



- (51) **International Patent Classification:**
A61K 39/39 (2006.01)
- (21) **International Application Number:**
PCT/EP2014/05 1860
- (22) **International Filing Date:**
30 January 2014 (30.01.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/759,75 1 1 February 2013 (01.02.2013) US
13 169596.7 28 May 2013 (28.05.2013) EP
- (71) **Applicant (for all designated States except US):** NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** BAUDNER, Barbara [DE/IT]; Novartis Vaccines and Diagnostics S.r.l, Via Fiorentina, 1, 1-53 100 Siena (IT). O'HAGAN, Derek [US/US]; Novartis Vaccines and Diagnostics, Inc, 350 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).
- (72) **Inventor; and**
- (71) **Applicant :** GALLORINI, Simona [IT/IT]; Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina, 1, 1-53 100 Siena (IT).
- (74) **Agents:** COURGEON, Antoine et al; Novartis Vaccines and Diagnostics S.r.l., Via Fiorentina 1, 1-53 100 Siena (IT).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2014/118305 A1

(54) **Title:** INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS

(57) **Abstract:** An intradermal delivery system comprises an immunogenic composition comprising a TLR agonist and immunogen and a microneedle. The immunogenic composition may comprise a solid biodegradable microneedle or a solid coated microneedle. The intradermal delivery system may be formulated into a skin patch.

INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS

TECHNICAL FIELD

This invention is in the field of vaccine delivery.

5 BACKGROUND ART

Vaccine compositions comprising Toll-like receptor (TLR) agonists are currently available and these vaccines are administered by intramuscular injection. Although effective, intramuscular administration can cause pain and local tissue damage, and fear of intramuscular injection is common. Intramuscular injections must be administered by medically trained personnel, preventing
10 quick administration and over-the counter sale. Intramuscular administration requires the use of liquid formulations which may lack stability over long periods of time.

It is an object of the invention to provide a different method of administering vaccines comprising TLR agonists, and in particular a more convenient way which do not suffer from the drawbacks mentioned above.

15 DISCLOSURE OF THE INVENTION

The inventors have surprisingly found that immunogenic compositions comprising a Toll-like receptor (TLR) agonist can provide a better immune response if they are delivered intradermally rather than intramuscularly. Increased numbers of cells expressing TLRs can be found in the dermis and epidermis in comparison to in the muscles, which may explain the improved response provided.
20 Moreover, intradermal delivery can cause significantly less pain than intramuscular delivery and can more easily permit self-administration of the composition, particularly when the intradermal delivery is achieved through use of multiple microneedles in the form of a microneedle device such as a skin patch. Accordingly, the invention provides a method of intradermally delivering an immunogenic composition comprising a TLR agonist and an immunogen.

25 The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a TLR agonist and an immunogen.

The invention also provides an intradermal delivery system comprising a solid immunogenic composition comprising a TLR agonist, an immunogen and a microneedle.


The invention also provides an intradermal delivery system comprising a solid biodegradable
30 microneedle, wherein the microneedle comprises a TLR agonist and an immunogen.

The invention also provides an intradermal delivery system comprising a solid microneedle, wherein the microneedle comprises a TLR agonist and a bacterial antigen.


The invention also provides an intradermal delivery system comprising a coated microneedle, wherein the microneedle comprises a TLR agonist and an immunogen, wherein the TLR agonist is
35 selected from a TLR2, TLR4, TLR5, TLR1, TLR6, TLR8 and a TLR9 agonist.

The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a TLR agonist, wherein the TLR agonist is:

- (a) a benzonaphthyridine TLR7 agonist;
- (b) a TLR7 agonist having formula T1 :



- (c) a TLR2 agonist having formula T2:



10 The invention also provides an intradermal delivery system comprising a solid immunogenic composition comprising a TLR agonist, an immunogen and a microneedle, wherein the TLR agonist is selected from a TLR2, TLR3, TLR4, TLR5, TLR1, TLR6, TLR8 and a TLR9 agonist, and the immunogen is not an influenza antigen.

The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a TLR3 agonist and an immunogen, wherein the immunogen is not an influenza antigen.

15 The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a TLR2 agonist and an immunogen, wherein the immunogen is a viral antigen, a bacterial antigen, a fungal antigen or a tumor antigen.

The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a TLR agonist and an immunogen, wherein the TLR agonist is selected from a TLR5 agonist, a TLR1 agonist and a TLR6 agonist.

20 The immunogenic composition may comprise a hollow needle. The hollow needle may be a hollow microneedle.

25 The invention also provides a process for preparing an intradermal delivery system or a skin patch of the invention. The process may comprise i) concentrating an antigen; ii) adding a TLR agonist to the concentrated antigen; iii) formulating an immunogenic composition from the concentrated antigen and the TLR agonist.

The invention also provides a process for preparing an intradermal delivery system comprising a solid microneedle, wherein the microneedle comprises a TLR agonist and an immunogen, wherein the method comprises the steps of a) mixing an immunogen and a TLR agonist to form an

immunogenic composition in which the immunogen has a concentration of 10mg/ml-50mg/ml and the TLR agonist has a concentration of 0.1mg/ml-10mg/ml and b) drying the immunogenic composition to form a solid microneedle.

5 The concentration of the immunogen may be 10mg/ml, 15mg/ml, 20mg/ml, 25mg/ml, 30mg/ml, 35mg/ml, 40mg/ml, 45mg/ml or 50mg/ml and the concentration of the TLR agonist may be 0.1 mg/ml, 0.2mg/ml, 0.3mg/ml, 0.4mg/ml, 0.5mg/ml, 0.6mg/ml, 0.7mg/ml, 0.8mg/ml, 0.9mg/ml, 1mg/ml, 2mg/ml, 3mg/ml, 4mg/ml, 5mg/ml, 6mg/ml, 7mg/ml, 8mg/ml, 9mg/ml or 10mg/ml.

The ratio of antigen to TLR agonist that is used may be around 10:1.

10 A preferred way of achieving intradermal delivery is via a skin patch (*e.g.* via a biodegradable microneedle or a coated microneedle) and so the invention also provides a skin patch for intradermal delivery of an immunogen having a plurality of microneedles, wherein the microneedles comprise a TLR agonist and the immunogen.

15 The immunogenic composition that is delivered intradermally is preferably solid, in contrast to the liquid compositions that are delivered through standard hollow intradermal needles. Solid immunogenic compositions may be in the form of a solid microneedle which can penetrate skin and deliver immunogenic compositions intradermally. The microneedle can itself be formed from the solid immunogenic composition (see solid biodegradable microneedles below), or the microneedle may penetrate the skin to deliver a separate immunogenic composition (see solid coated microneedles below).

20 The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a CD1d agonist and an immunogen.

The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a CLR agonist and an immunogen.

25 The invention also provides an intradermal delivery system comprising an immunogenic composition comprising a mutant *E.coli* heat-labile toxin, an immunogen and a microneedle.

Intradermal delivery

30 Intradermal delivery of a composition may be achieved using any mode of delivery in which the composition is supplied to the dermis, but does not pass through the dermis to the muscle, including those where the composition is delivered directly to the dermis (*e.g.* by a needle which passes entirely through the epidermis to the dermis) and those where the composition is first delivered into the epidermis by penetration of the epidermis (*e.g.* by a needle, where the composition then moves through the epidermis to the dermis). Intradermal delivery contrasts with the intramuscular delivery of the prior art which requires that the delivery system penetrates through both the epidermis (typically about 100µm thick in humans) and the dermis (typically about 0.6-3mm thick in humans)
35 and the composition is then delivered into the muscle.

Suitable intradermal delivery systems include, but are not limited to, those based on microneedles. Microneedles are solid, as opposed to hollow, which retain their structural integrity during storage and insertion, and are shaped so that they can penetrate a subject's skin when applied thereto. The mechanical characteristics which are required for skin penetration depend on the target organism, but they preferably have sufficient strength to penetrate human skin whilst remaining substantially intact. Materials for forming suitable needles are readily available (see below) and these can be tested to determine appropriate characteristics for any particular need. Microneedle delivery of vaccines was reviewed in references 1 and 2.

Solid microneedles differ from standard hollow needles because they do not comprise a cavity through which the immunogenic composition passes as a liquid, but rather the form of the microneedle is such that a solid immunogenic composition either is present on the outside of the needle, or itself forms the needle.

The microneedles can penetrate the skin. They are long enough to penetrate through the epidermis to deliver material into the dermis and thus achieve intradermal delivery, but they ideally are not so long that they can penetrate into or past the hypodermis. The length of the needle depends on the target organism, and the length required to reach the dermis of the particular target organism. Therefore for use in humans, they will typically be 100-2500µm long *e.g.* about 500µm, about 1000µm, or about 1500µm. At the time of delivery the tip of a microneedle may penetrate the dermis, while its base remains in the epidermis.

The microneedles can have various shapes and geometries *e.g.* see figure 2 of reference 3. They will typically be tapered with a skin-facing point *e.g.* shaped as pyramids or cones. A tapered microneedle with a widest diameter of <500µm is typical. Structural parameters (including shape, tip radius, base radius, pitch, height, density, and total pore volume) have been studied in detail (*e.g.* see references 3-6) and can be modified according to particular needs or desires in any chosen situation.

Microneedles are preferably not used singly but, rather, multiple needles are applied simultaneously using a microneedle device *e.g.* as a skin patch comprising a plurality of microneedles. A single patch will typically include a plurality of microneedles *e.g.* >10, >20, >30, >40, >50, >60, >70, >80, >90, >100, >200, >300, >400, >500, >750, ≥1000 or more per patch. Where a patch includes a plurality of microneedles, it may comprise a backing layer to which all of the microneedles are attached. A unitary backing layer with ≥20 projecting microneedles is typical *e.g.* 50-600 microneedles per patch. Where a patch includes a plurality of microneedles, these can be arranged in a regular repeating pattern or array, or they may be arranged irregularly. Spacing of microneedles can be an important parameter for controlling permeability [3,4] and it can be adjusted according to particular situations.

A patch will typically have an area of 3cm² or less, for example <2cm² or <1cm². A circular patch with a diameter of between 0.5cm and 1.5cm is useful.

The density of microneedles on a patch can vary, but may be $\geq 10\text{cm}^{-2}$, $\geq 20\text{cm}^{-2}$, $\geq 30\text{cm}^{-2}$, $\geq 40\text{cm}^{-2}$, $\geq 50\text{cm}^{-2}$, $\geq 60\text{cm}^{-2}$, $\geq 70\text{cm}^{-2}$, $\geq 80\text{cm}^{-2}$ or more.

A patch of the invention has a skin-facing inner face and an environment-facing outer face. The inner face may include an adhesive to facilitate adherence to a subject's skin. When present, it is preferably not present on the microneedles themselves *i.e.* the microneedles are adhesive-free. Thus the inner face will typically have an outer adhesive margin or annulus for adhering the patch to skin *e.g.* as seen in sticking plasters or nicotine patches. The adhesive region and the microneedles can be provided as an integral unit, or the adhesive region can be made by adding a backing which extends outwards beyond the microneedles to provide the outer adhesive margin or annulus for adhering the patch to skin *e.g.* as seen in sticking plasters or nicotine patches.

Patches may be packaged into individual pouches *e.g.* sealed under nitrogen, then heat sealed. They should be stored carefully to avoid damage to the microneedles. Patches of the invention may comprise adhesives which comprise tackifiers. Tackifiers are substances which increase the adhesivity of the patch therefore preventing the patch from falling off the subject's skin. If the immunogenic composition on the inner face of the patch crystallises, the patch can fall off the subject's skin. Therefore crystallisation inhibitors can be added to the immunogenic composition to prevent the composition from crystallising.

Microneedles can be hollow, such that an immunogenic composition can pass through them and thus arrive in the dermis. A preferred option, however, uses solid non-hollow microneedles. Useful solid needles include biodegradable and non-biodegradable needles. Biodegradable needles can (if desired) be left in the skin after being applied, and immunogen can be incorporated into the needles themselves during manufacture, such that immunogen is released as the needles degrade or dissolve *in situ*. Non-biodegradable solid needles must be removed some time after being applied and immunogen is typically present as a dry coating on the external face of the solid needles.

25 Solid biodegradable microneedles

One useful solid microneedle format for use in the invention is a solid biodegradable microneedle. Immunogen is incorporated within the microneedle, such that the needle is structurally composed of both the immunogen and suitable solid excipients. The solid excipients provide mechanical strength to permit the microneedles to be inserted into a subject's skin, where the immunogen can be released.

30 The microneedles are biosoluble and biodegradable. Thus the needle can dissolve in the skin after the microneedle is applied, in contrast to the coated microneedles used in references 7 & 8 (see below). Having dissolved, the needle material will then be metabolised to give harmless end-products. The timescale for dissolving after applying the patch can vary, but dissolving will typically commence immediately after applying the patch (*e.g.* within 10 seconds) and may continue for *e.g.* up to 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 1 hour, 5 hours, 10 hours, or 24 hours, until the microneedle has fully dissolved (although the needles might be removed before dissolution is complete). Materials with suitable *in vivo* dissolving kinetics are readily available (as described

below) and these can be varied and tested to determine appropriate concentrations *etc.* for any desired dissolution profile.

Suitable materials for forming the microneedles will typically be biosoluble and biodegradable polymers, and these may comprise one or more carbohydrates. Short-chain carbohydrates can also be used. For example, the material may comprise a cellulose, a dextrin, a dextran, a disaccharide, a chitosan, a chitin, *etc.*, or mixtures thereof. Hyaluronates can also be used [9], as can polylactic acids [10]. As an alternative to carbohydrate materials, polymers such as polyvinylpyrrolidone (PVP) can be used, or copolymers of methylvinylether and either maleic acid or maleic anhydride (PMVE/MA), such as Gantrez™ AN-139 [6,11]. Other GRAS materials may also be used.

Suitable celluloses include, but are not limited to, cellulose, carboxymethyl-celluloses, hydroxypropyl-celluloses, hydroxyethyl cellulose, and hydroxypropyl methylcellulose. Suitable dextrans include, but are not limited to, maltodextrin, cyclodextrin, amylopectin, icodextrin, yellow dextrin, and white dextrans. Suitable disaccharides include, but are not limited to, sucrose, lactose, maltose, trehalose, turanose, and cellobiose. One suitable material for forming biosoluble and biodegradable microneedles is a dextrin/trehalose mixture. Further suitable carbohydrates are amylopectins [12]. Formulation excipients can easily be added to the immunogenic compositions of the solid biodegradable microneedles to improve stability of the composition and to provide a process of manufacture which is both robust and scalable. The polymers of solid biodegradable microneedles can provide the advantage of stabilising antigens. Such an advantage may be provided by the polymers of the microneedles or co-polymers having carbohydrate groups which have a stabilising effect on the antigens. Shelf life of the intradermal delivery system can therefore be extended.

The antigen capacity of solid biodegradable microneedles can be higher than other microneedles, which provides the advantage of allowing usability in combination with antigens which require high levels of immunogen to be provided in each needle, such as tetravalent influenza,

These needles can be made in various ways *e.g.* by following the techniques and guidance in references 12 to 19. For instance, a mold with microneedle cavities can be prepared. A matrix material (*e.g.* a mixture of dextrin and trehalose) can be combined with an immunogen and this aqueous material is then centrifugally cast in the mold to form an array of solid microneedles. A cellulose gel can then be cast over the matrix/immunogen mixture (*e.g.* which mixture has formed a film) to form a backing layer on the patch. When this backing layer has dried, it can be removed to give a patch from which the solid microneedles project. An alternative method involves the *in situ* polymerisation in a suitable mold *e.g.* an immunogen can be mixed with a liquid monomer (such as vinyl pyrrolidone) within a patch mold and this mixture can be photopolymerised. In such a process the immunogen is ideally present in dried (*e.g.* lyophilised) form such that it becomes encapsulated during polymerisation. Molding of hydrogels [12] or particles [20] can also be used. Molds for these processes can be made in various ways *e.g.* by laser-based micromolding [6], by etching, *etc.*

Thus a manufacturing process may comprise: (a) mixing a biosoluble and biodegradable matrix material with an immunogen, usually by reconstituting a lyophilised immunogen; (b) adding the mixture from step (a) to a mold containing cavities for forming microneedles; (c) letting the mixture set in the mold, to form solid microneedles; (d) optionally, applying material to the set microneedles to provide a backing layer; and (e) removing the microneedles (and optional backing layer) from the mold. An alternative manufacturing process may comprise: (a) mixing a polymerisable monomer with an immunogen, usually a lyophilised immunogen; (b) adding the mixture from step (a) to a mold containing cavities for forming microneedles; (c) polymerising monomer within the mixture in the mold, to form solid microneedles; (d) optionally, applying material to the solid microneedles to provide a backing layer; and (e) removing the microneedles (and optional backing layer) from the mold.

Solid biodegradable microneedles are ideally provided as an array on a patch. As mentioned above, the patch can have two portions, which can suitably take the form of an inner disc and an outer annulus. The microneedles may be provided on a first inner portion of the patch, and a second outer portion can include an adhesive. This patch can be placed on the skin and pressed down so that the outer portion adheres to the skin, while the microneedles on the inner portion penetrate the epidermis. Such arrays may be produced by soft lithography or photolithography.

Dissolving microneedle arrays were shown in reference 21 to be suitable for eliciting protection against tetanus, diphtheria, malaria, and influenza (see also reference 16). Solid biodegradable microneedles are advantageous over other forms of needles due to the lack of sharp surfaces on the needle. Therefore solid biodegradable needles provide increased levels of safety and may allow for over the counter sale and self-administration.

Furthermore, formulation of immunogenic compositions as solid biodegradable microneedles can be achieved more easily than the immunogenic compositions used with the solid coated microneedles discussed below. Many immunogenic compositions comprise detergents, particularly those based on viral surface antigens. These detergents can cause difficulties when preparing coated microneedles, so biodegradable microneedles provide an advantage for such compositions.

Solid coated microneedles

Another useful solid microneedle format for use in the invention is a solid, non-hollow, non-biodegradable microneedle. The microneedle is made from a material which has mechanical strength to permit insertion into a subject's skin. Immunogen is coated onto the needles and, after they have been injected, immunogen is released from the coating. The MACROFLUX™ (Zosano), MTS™ (3M) and IMMUNPATCH™ technologies are examples of such delivery systems.

The microneedles are solid and remain intact after insertion into a patient's skin (in contrast to the biodegradable microneedles discussed above). Materials for forming suitable solid needles are readily available and these can be tested and selected for any particular need e.g. metals (such as stainless steel), polymers (such as polycarbonate, ideally medical grade), or silicon. Metal needles can be fabricated by using laser cutting and electro-polishing [24] or etching [22]. Polymer needles

can be fabricated by microreplication and/or micromolding (including injection molding). Silicon needles can be made by etching [4,23]. Suitable microneedles are disclosed in references 7, 8, and 24-28.

5 Immunogen is coated onto the microneedles. Coating may be achieved by applying either a liquid coating which then forms a solid coating (*e.g.* by drying), or by applying a solid coating directly. Coating can be achieved by a simple process such as dip-coating *e.g.* involving a dipping step then a drying step (*e.g.* by evaporation), with repetition as required. Other useful coating techniques are disclosed in reference 26. Spray coating can also be used, with sugar-based formulations to provide a dry coating [29]. Thus a process of the invention may comprise: applying an immunogen to the
10 surface of one or more solid microneedles to provide a coated microneedle device for injection of the vaccine.

A coating solution for applying to the needles can include one or more biosoluble and biodegradable matrix materials, such as those discussed above for formation of biodegradable needles, and in particular by incorporating carbohydrates. Thus a process of the invention may comprise: (a) mixing
15 a biosoluble and biodegradable matrix material with an immunogen; and (b) applying the mixture from step (a) to the surface of one or more solid microneedles to provide a coated microneedle device for injection of the immunogen. Coating may be enhanced by using one or more "deposition enhancing components" as described in reference 26.

The applying steps discussed above may comprise an application sub-step followed by a drying
20 sub-step, and this pair of sub-steps can be performed once or more than once *e.g.* 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times.

Coated solid microneedle arrays were used in reference 22 with influenza virus immunogens and were shown to activate both humoral and cellular arms of the immune response and confer improved long-term protection.

25 ***Toll-like receptor agonists***


Compositions of the invention include a TLR agonist *i.e.* a compound which can agonise a Toll-like receptor. Most preferably, a TLR agonist is an agonist of a human TLR. The TLR agonist can activate any of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 or TLR11; preferably it can activate human TLR4 or human TLR7.

30 A composition of the invention can include more than one TLR agonist. These two agonists are different from each other and they can target the same TLR or different TLRs.

Agonist activity of a compound against any particular Toll-like receptor can be determined by standard assays. Companies such as Imgenex and Invivogen supply cell lines which are stably co-transfected with human TLR genes and **NFKB**, plus suitable reporter genes, for measuring TLR
35 activation pathways. They are designed for sensitivity, broad working range dynamics and can be used for high-throughput screening. Constitutive expression of one or two specific TLRs is typical in such cell lines. See also reference 30. Many TLR agonists are known in the art *e.g.* reference 31

describes certain lipopeptide molecules that are TLR2 agonists, references 32 to 35 each describe classes of small molecule agonists of TLR7, and references 36 & 37 describe TLR7 and TLR8 agonists for treatment of diseases.

TLR7 agonists which can be used with the invention can be benzonaphthyridines, such as those having formula T1:



where

R^1 is H, Ci-C₆alkyl, -C(R⁵)₂OH, -I⁵, -L¹R⁶, -L²R⁵, -L²R⁶, -OL²R⁵, or -OL²R⁶;

L¹ is -C(O)- or -O-;

L² is Ci-C₆alkylene, C2-C₆alkenylene, arylene, heteroarylene or -
 ((CR⁴R⁴)_pO)_q(CH₂)_p-, wherein the Ci-C₆alkylene and C2-C₆alkenylene of L² are
 optionally substituted with 1 to 4 fluoro groups;

each L³ is independently selected from Ci-C₆alkylene and -((CR⁴R⁴)_pO)_q(CH₂)_p-,

wherein the Ci-C₆alkylene of L³ is optionally substituted with 1 to 4 fluoro groups;

L⁴ is arylene or heteroarylene;

R² is H or Ci-C₆alkyl;

R³ is selected from Ci-C₄alkyl, -L³R⁵, -I⁵, -L³R⁷, -L³L⁴L³R⁷, -L³L⁴R⁵, -L³L⁴L³R⁵, -
 OL³R⁵, -OL³R⁷, -OL³L⁴R⁷, -OL³L⁴L³R⁷, -OR⁸, -OL³L⁴R⁵, -OL³L⁴L³R⁵ and -
 C(R⁵)₂OH;

each R⁴ is independently selected from H and fluoro;

R⁵ is -P(O)(OR⁹)₂,

R⁶ is -CF₂P(O)(OR⁹)₂ or -C(O)OR¹⁰;

R⁷ is -CF₂P(O)(OR⁹)₂ or -C(O)OR¹⁰;

R⁸ is H or Ci-C₄alkyl;


each R⁹ is independently selected from H and Ci-C₆alkyl;

R¹⁰ is H or Ci-C₄alkyl;

each p is independently selected from 1, 2, 3, 4, 5 and 6, and


q is 1, 2, 3 or 4.

Further details of these compounds are disclosed in reference 38, and the invention can use any of
 compounds 1 to 28 from reference 38. Preferred examples of compounds of formula T1 include:



Other useful TLR7 agonists include, but are not limited to, or any of compounds 1 to 247 disclosed in reference 34, or any of compounds 1 to 102 from reference 39.

TLR2 agonists which can be used with the invention can be lipopeptides having formula T2:



5

wherein:

R^1 is H, $-C(O)-C_{7-8}alkyl$ or $-C(O)-C_{6-8}alkyl$;

R^2 is $C_{7-8}alkyl$;

R^3 is $C_{7-8}alkyl$;

10 L_1 is $-CH_2OC(O)-$, $-CH_2O-$, $-CH_2NR^7C(O)-$ or $-CH_2OC(O)NR^7-$;

L_2 is $-OC(O)-$, $-O-$, $-NR^7C(O)-$ or $-OC(O)NR^7-$;

R^4 is $-L_3R^5$ or $-L_4R^5$;

R^5 is $-N(R^7)_2$, $-OR^7$, $-P(O)(OR^7)_2$, $-C(O)OR^7$, $-NR^7C(O)L_3R^8$, $-NR^7C(O)L_4R^8$, $-OL_3R^6$, $-C(O)NR^7L_3R^8$, $-C(O)NR^7L_4R^8$, $-S(O)_2OR^7$, $-OS(O)_2OR^7$, $Ci-C_6alkyl$, a C_6aryl , a $Cioaryl$, a Ci_4aryl , 5 to 14 ring membered heteroaryl containing 1 to 3 heteroatoms selected from O, S and N, $C_3-Cscycloalkyl$ or a 5 to 6 ring membered

15

heterocycloalkyl containing 1 to 3 heteroatoms selected from O, S and N, wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R⁵ are each unsubstituted or the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R⁵ are each substituted with 1 to 3 substituents independently selected from -OR⁹, -OL₃R⁶, -OL₄R⁶, -OR⁷, and -C(=O)OR⁷;

L₃ is a Ci-Cioalkylene, wherein the Ci-Cioalkylene of L₃ is unsubstituted, or the Ci-Cioalkylene of L₃ is substituted with 1 to 4 R⁶ groups, or the Ci-Cioalkylene of L₃ is substituted with 2 Ci-Cealkyl groups on the same carbon atom which together, along with the carbon atom they are attached to, form a C₃-Cscycloalkyl;

L₄ is -((CR⁷R⁷)_pO)_q(CR¹⁰R¹⁰)_p- or -(CR¹¹R¹¹)((CR⁷R⁷)_pO)_q(CR¹⁰R¹⁰)_p-, wherein each R¹¹ is a Ci-C₆alkyl groups which together, along with the carbon atom they are attached to, form a C₃-Cscycloalkyl;

each R⁶ is independently selected from halo, Ci-Cealkyl, Ci-C₆alkyl substituted with 1-2 hydroxyl groups, -OR⁷, -N(R⁷)₂, -C(=O)OH, -C(=O)N(R⁷)₂, -P(=O)(OR⁷)₂, a C₆aryl, a Cioaryl and a Cnaryl;

each R⁷ is independently selected from H and Ci-Cealkyl;

R⁸ is selected from -SR⁷, -C(=O)OH, -P(=O)(OR⁷)₂, and a 5 to 6 ring membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O and N;


R⁹ is phenyl;

each R¹⁰ is independently selected from H and halo;

each p is independently selected from 1, 2, 3, 4, 5 and 6, and








q is 1, 2, 3 or 4.

Further details of these compounds are disclosed in reference 40, and the invention can use any of the compounds disclosed therein *e.g.* examples 1-92 thereof, and the compounds listed in claim 17 thereof. Another useful TLR2 agonist is palmitoyl-Cys(2[R],3-dilauroyloxy-propyl)-Abu-D-Glu-NH₂, where: Cys is a cysteine residue, Abu is an aminobutyric acid residue and Glu is a glutamic acid residue. This compound is disclosed in example 16 of re. 31, and has formula T3a:




The agonist of formula T1 or T2 or T3a can be present as a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate (*e.g.* hydrate), as a N-oxide derivative, as an isomer (including a tautomer or an enantiomer) or a mixture of isomers, *etc.* One particularly useful salt is the arginine salt of compound Tic, which can be used as the arginine salt monohydrate.

Other useful TLR agonists are the following compounds:


 <p>as defined on pages 2-7 of reference 33;</p>	 <p>as defined on pages 2-5 & 7-8 of ref. 33;</p>
 <p>as defined on pages 6 and 7 of reference 32;</p>	 <p>as defined on pages 2 to 5 of reference 35;</p>
 <p>as defined on pages 5 to 6 of reference 36;</p>	 <p>as defined on pages 2 to 3 of reference 41;</p>
 <p>as defined on pages 2-4 of reference 34</p>	

Various useful TLR4 agonists are known in the art, many of which are analogs of endotoxin or lipopolysaccharide (LPS), or of monophosphoryl lipid A ('MPLA'). For instance, a TLR4 agonist used with the invention can be:

- 5 (i) 3d-MPL (*i.e.* 3-O-deacylated monophosphoryl lipid A; also known as 3-de-O-acylated monophosphoryl lipid A or 3-O-desacyl-4'-monophosphoryl lipid A). This derivative of the monophosphoryl lipid A portion of endotoxin has a de-acylated position 3 of the reducing end of glucosamine. It has been prepared from a heptoseless mutant of *Salmonella Minnesota*, and is chemically similar to lipid A but lacks an acid-labile phosphoryl group and a base-labile acyl group. Preparation of 3d-MPL was originally described in ref. 42, and
10 the product has been manufactured and sold by Corixa Corporation. It is present in GSK's 'AS04' adjuvant. Further details can be found in references 43 to 46.
- (ii) glucopyranosyl lipid A (GLA) [47] or its ammonium salt *e.g.*




- 15 (iii) an aminoalkyl glucosaminide phosphate, such as RC-529 or CRX-524 [48-50]. RC-529 and CRX-524 have the following structure, differing by their R₂ groups:




$R_1 = H, R_2 = n-C_{13}H_{27}CO, n=1$ (RC-529)

$R_1 = H, R_2 = n-C_gH_{14}gCO, n=1$ (CRX-524)


(iv) compounds containing lipids linked to a phosphate-containing acyclic backbone, such as E5564 [51,52]:



5 (v) A compound of formula I, II or III as defined in reference 53, or a salt thereof, such as compounds 'ER 803058', 'ER 803732', 'ER 804053', 'ER 804058', 'ER 804059', 'ER 804442', 'ER 804680', 'ER 803022', 'ER 804764' or 'ER 804057'. ER 804057 is also known as E6020 and it has the following structure:



whereas ER 803022 has the following structure:



(vi) One of the polypeptide ligands disclosed in reference 54.

- 5 Preferred TLR4 agonists are analogs of monophosphoryl lipid A (MPL)


Other biological receptors

The invention is defined above and below by reference to TLR agonists, but it can be more widely applied to other small molecule immunopotentiators (SMIPs) which do not act via TLRs. In particular, SMIPs which may be used with the invention may agonise C-type lectin receptors (CLRs) or CD1d rather than (or in addition to) a TLR. Thus the present disclosure includes the invention as described above with reference to TLR agonism, but wherein references to a TLR agonist (or similar) are replaced by reference either to a CLR agonist or to a CD1d agonist.

10

CLR agonists include, but are not limited to, trehalose-6,6'-dimycolate (TDM), its synthetic analog D-(+)-trehalose-6,6'-dibehenate (TDB), and other 6,6'-diesters of trehalose and fatty acids. Thus the invention can be applied to trehalose esters and diacyl trehaloses which are CLR agonists. These agonists may have formula (C):

15



where R¹O- and R²C(O)- are the same or different and are acyl groups. Suitable acyl groups may be saturated or unsaturated. They may be selected from the acyl residues of a mycolic acid, a corynomycolic acid, a 2-tetradecyl-3-hydroxyoctadecanoic acid, a 2-eicosyl-3-hydroxytetracosanoic acid, a bourgeanic acid, a behenic acid, a palmitic acid, *etc.* Useful mycolic acids include alpha-, methoxy-, and keto- mycolic acids, in cis- and or trans- forms.

CDId agonists include, but are not limited to, a-glycosylceramides [55-64] such as a-galactosylceramides. Thus the invention can be applied to glycosylceramides which are CDId agonists, including a-galactosylceramide (a-GalCer), phytosphingosine-containing a-glycosylceramides, [(2S,3S,4R)-1-0-(a-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol], OCH, KRN7000 CRONY-101, 3"-0-sulfo-galactosylceramide, *etc.*

Mutant E.coli heat-labile toxin

The invention is defined above and below by reference to TLR agonists, but it can also be applied to proteinaceous adjuvants which do not act via TLRs, such as mutant *E.coli* heat-labile toxins. Thus the present disclosure includes the invention as described above with reference to TLR agonism, but wherein references to a TLR agonist (or similar) are replaced by reference to a mutant *E.coli* heat-labile toxin which displays reduced enzymatic activity compared to the wild-type toxin [65,66,67]. Various such mutants are known *e.g.* reference 68.

Suitable mutant *E.coli* heat-labile toxins include, but are not limited to, a K63 mutant (in which the wild-type Ser-63 in the enzymatically active A-subunit is mutated to Lys [68,69]) and a R72 mutant (in which wild-type Ala-72 is mutated to Arg [69,70]), or a double K63/R72 mutant [71]. The G192 mutant can also be used, in which wild-type Arg is mutated to Gly.

IininImogens

The invention can be used to deliver a wide range of immunogens, for treating or protecting against a wide range of diseases. The immunogen may elicit an immune response that protects against a viral disease (*e.g.* due to an enveloped or non-enveloped virus), a bacterial disease (*e.g.* due to a Gram negative or a Gram positive bacterium), a fungal disease, a parasitic disease, an auto-immune disease, or any other disease. The immunogen may also be useful in immunotherapy *e.g.* for treating a tumour/cancer, Alzheimer's disease, or an addiction.

The immunogen may take various forms *e.g.* a whole organism, an outer-membrane vesicle, a polypeptide, a saccharide, a liposaccharide, a conjugate (*e.g.* of a carrier and a hapten, or of a carrier and a saccharide), *etc.* Where the immunogen is a polypeptide, it will typically be a surface polypeptide *e.g.* an adhesin, a hemagglutinin, an envelope glycoprotein, a spike glycoprotein, *etc.*

The immunogen may be produced by expression in an organism that differs from the organism which causes the disease which the immunogen provides an immune response against. However, a viral immunogen is an immunogen which elicits an immune response against a viral disease, even if the viral immunogen is expressed in a bacterium. Similarly, an immunogen that elicits an immune response against a bacterial disease is a bacterial immunogen, irrespective of how the immunogen was produced. For example, an HIV immunogen that is expressed in *E.coli* is a viral immunogen, rather than a bacterial immunogen.

Viral Antigens

Viral antigens suitable for use in the immunogenic compositions provided herein include, but are not limited to, inactivated (or killed) virus, attenuated virus, split virus formulations, purified subunit formulations, viral proteins which may be isolated, purified or derived from a virus, Virus Like Particles (VLPs) and polynucleotide antigens which may be isolated, purified or derived from a virus or recombinantly synthesized. In certain embodiments, viral antigens are derived from viruses propagated on cell culture or other substrate. In other embodiments, viral antigens are expressed recombinantly. In certain embodiments, viral antigens preferably include epitopes which are exposed on the surface of the virus during at least one stage of its life cycle. Viral antigens are preferably conserved across multiple serotypes or isolates. Viral antigens suitable for use in the immunogenic compositions provided herein include, but are not limited to, antigens derived from one or more of the viruses set forth below as well as the specific antigens examples identified below.

Orthomyxovirus: Viral antigens include, but are not limited to, those derived from an Orthomyxovirus, such as Influenza A, B and C. In certain embodiments, orthomyxovirus antigens are selected from one or more of the viral proteins, including hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix protein (M1), membrane protein (M2), one or more of the transcriptase components (PB1, PB2 and PA). In certain embodiments the viral antigen include HA and NA. In certain embodiments, the influenza antigens are derived from interpandemic (annual) flu strains, while in other embodiments, the influenza antigens are derived from strains with the potential to cause pandemic a pandemic outbreak (i.e., influenza strains with new haemagglutinin compared to the haemagglutinin in currently circulating strains, or influenza strains which are pathogenic in avian subjects and have the potential to be transmitted horizontally in the human population, or influenza strains which are pathogenic to humans).

Paramyxoviridae viruses: Viral antigens include, but are not limited to, those derived from Paramyxoviridae viruses, such as Pneumoviruses (RSV), Paramyxoviruses (PIV), Metapneumovirus and Morbilliviruses (Measles).

Pneumovirus: Viral antigens include, but are not limited to, those derived from a Pneumovirus, such as Respiratory syncytial virus (RSV), Bovine respiratory syncytial virus, Pneumonia virus of mice, and Turkey rhinotracheitis virus. Preferably, the

Pneumovirus is RSV. In certain embodiments, pneumovirus antigens are selected from one or more of the following proteins, including surface proteins Fusion (F), Glycoprotein (G) and Small Hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P and L and nonstructural proteins NS1 and NS2. In other
5 embodiments, pneumovirus antigens include F, G and M. In certain embodiments, pneumovirus antigens are also formulated in or derived from chimeric viruses, such as, by way of example only, chimeric RSV/PIV viruses comprising components of both RSV and PIV.

Paramyxovirus: Viral antigens include, but are not limited to, those derived from a
10 Paramyxovirus, such as Parainfluenza virus types 1 - 4 (PIV), Mumps, Sendai viruses, Simian virus 5, Bovine parainfluenza virus, Nipahvirus, Henipavirus and Newcastle disease virus. In certain embodiments, the Paramyxovirus is PIV or Mumps. In certain
15 embodiments, paramyxovirus antigens are selected from one or more of the following proteins: Hemagglutinin -Neuraminidase (HN), Fusion proteins F1 and F2, Nucleoprotein (NP), Phosphoprotein (P), Large protein (L), and Matrix protein (M). In
20 other embodiments, paramyxovirus proteins include HN, F1 and F2. In certain embodiments, paramyxovirus antigens are also formulated in or derived from chimeric viruses, such as, by way of example only, chimeric RSV/PIV viruses comprising
25 components of both RSV and PIV. Commercially available mumps vaccines include live attenuated mumps virus, in either a monovalent form or in combination with measles and rubella vaccines (MMR). In other embodiments, the Paramyxovirus is
30 Nipahvirus or Henipavirus and the antigens are selected from one or more of the following proteins: Fusion (F) protein, Glycoprotein (G) protein, Matrix (M) protein, Nucleocapsid (N) protein, Large (L) protein and Phosphoprotein (P).

Poxviridae: Viral antigens include, but are not limited to, those derived from *Orthopoxvirus*
such as *Variola vera*, including but not limited to, *Variola major* and *Variola minor*.

Metapneumovirus: Viral antigens include, but are not limited to, Metapneumovirus, such as
human metapneumovirus (hMPV) and avian metapneumoviruses (aMPV). In certain
30 embodiments, metapneumovirus antigens are selected from one or more of the following proteins, including surface proteins Fusion (F), Glycoprotein (G) and Small Hydrophobic protein (SH), matrix proteins M and M2, nucleocapsid proteins N, P and L.
In other embodiments, metapneumovirus antigens include F, G and M. In certain
35 embodiments, metapneumovirus antigens are also formulated in or derived from chimeric viruses.

Morbillivirus: Viral antigens include, but are not limited to, those derived from a
Morbillivirus, such as Measles. In certain embodiments, morbillivirus antigens are
40 selected from one or more of the following proteins: hemagglutinin (H), Glycoprotein (G), Fusion factor (F), Large protein (L), Nucleoprotein (NP), Polymerase phosphoprotein (P), and Matrix (M). Commercially available measles vaccines include

live attenuated measles virus, typically in combination with mumps and rubella (MMR).

Picornavirus: Viral antigens include, but are not limited to, those derived from Picornaviruses, such as Enteroviruses, Rhinoviruses, Heparnavirus, Cardioviruses and Aphthoviruses. In certain embodiments, the antigens are derived from Enteroviruses, while in other embodiments the enterovirus is Poliovirus. In still other embodiments, the antigens are derived from Rhinoviruses. In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

Enterovirus: Viral antigens include, but are not limited to, those derived from an Enterovirus, such as Poliovirus types 1, 2 or 3, Coxsackie A virus types 1 to 22 and 24, Coxsackie B virus types 1 to 6, Echovirus (ECHO) virus) types 1 to 9, 11 to 27 and 29 to 34 and Enterovirus 68 to 71. In certain embodiments, the antigens are derived from Enteroviruses, while in other embodiments the enterovirus is Poliovirus. In certain embodiments, the enterovirus antigens are selected from one or more of the following Capsid proteins VPO, VP1, VP2, VP3 and VP4. Commercially available polio vaccines include Inactivated Polio Vaccine (IPV) and Oral poliovirus vaccine (OPV). In certain embodiments, the antigens are formulated into virus-like particles.

Bunyavirus: Viral antigens include, but are not limited to, those derived from an *Orthobunyavirus*, such as California encephalitis virus, a *Phlebovirus*, such as Rift Valley Fever virus, or a *Nairovirus*, such as *Crimean-Congo hemorrhagic fever* virus.

Rhinovirus: Viral antigens include, but are not limited to, those derived from rhinovirus. In certain embodiments, the rhinovirus antigens are selected from one or more of the following Capsid proteins: VPO, VP1, VP2, VP2 and VP4. In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

Heparnavirus: Viral antigens include, but are not limited to, those derived from a Heparnavirus, such as, by way of example only, Hepatitis A virus (HAV). Commercially available HAV vaccines include inactivated HAV vaccine.

Togavirus: Viral antigens include, but are not limited to, those derived from a Togavirus, such as a Rubivirus, an Alphavirus, or an Arterivirus. In certain embodiments, the antigens are derived from Rubivirus, such as by way of example only, Rubella virus. In certain embodiments, the togavirus antigens are selected from E1, E2, E3, C, NSP-1, NSPO-2, NSP-3 or NSP-4. In certain embodiments, the togavirus antigens are selected from E1, E2 or E3. Commercially available Rubella vaccines include a live cold-adapted virus, typically in combination with mumps and measles vaccines (MMR).

Flavivirus: Viral antigens include, but are not limited to, those derived from a Flavivirus, such as Tick-borne encephalitis (TBE) virus, Dengue (types 1, 2, 3 or 4) virus, Yellow Fever virus, Japanese encephalitis virus, Kyasanur Forest Virus, West Nile encephalitis virus, St. Louis encephalitis virus, Russian spring-summer encephalitis virus, Powassan encephalitis virus. In certain embodiments, the flavivirus antigens are selected from

PrM, M, C, E, NS-1, NS-2a, NS2b, NS3, NS4a, NS4b, and NS5. In certain embodiments, the flavivirus antigens are selected from PrM, M and E. Commercially available TBE vaccine includes inactivated virus vaccines. In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

5 *Pestivirus*: Viral antigens include, but are not limited to, those derived from a Pestivirus, such as Bovine viral diarrhea (BVDV), Classical swine fever (CSFV) or Border disease (BDV).

10 *Hepadnavirus*: Viral antigens include, but are not limited to, those derived from a Hepadnavirus, such as Hepatitis B virus. In certain embodiments, the hepadnavirus antigens are selected from surface antigens (L, M and S), core antigens (HBc, HBe). Commercially available HBV vaccines include subunit vaccines comprising the surface antigen S protein.

15 *Hepatitis C virus*: Viral antigens include, but are not limited to, those derived from a Hepatitis C virus (HCV). In certain embodiments, the HCV antigens are selected from one or more of E1, E2, E1/E2, NS3/45 polyprotein, NS 3/45-core polyprotein, core, and/or peptides from the nonstructural regions. In certain embodiments, the Hepatitis C virus antigens include one or more of the following: HCV E1 and or E2 proteins, E1/E2 heterodimer complexes, core proteins and non-structural proteins, or fragments of these antigens, wherein the non-structural proteins can optionally be modified to remove enzymatic activity but retain immunogenicity. In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

20 *Rhabdovirus*: Viral antigens include, but are not limited to, those derived from a Rhabdovirus, such as a Lyssavirus (Rabies virus) and Vesiculovirus (VSV). Rhabdovirus antigens may be selected from glycoprotein (G), nucleoprotein (N), large protein (L), nonstructural proteins (NS). Commercially available Rabies virus vaccine comprise killed virus grown on human diploid cells or fetal rhesus lung cells.

25 *Caliciviridae*: Viral antigens include, but are not limited to, those derived from Calciviridae, such as Norwalk virus, and Norwalk-like Viruses, such as Hawaii Virus and Snow Mountain Virus. In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

30 *Coronavirus*: Viral antigens include, but are not limited to, those derived from a Coronavirus, SARS, Human respiratory coronavirus, Avian infectious bronchitis (IBV), Mouse hepatitis virus (MHV), and Porcine transmissible gastroenteritis virus (TGEV). In certain embodiments, the coronavirus antigens are selected from spike (S), envelope (E), matrix (M), nucleocapsid (N), and Hemagglutinin-esterase glycoprotein (HE). In certain
35 embodiments, the coronavirus antigen is derived from a SARS virus. In certain embodiments, the coronavirus is derived from a SARS viral antigen as described in WO 04/92360.

Retrovirus: Viral antigens include, but are not limited to, those derived from a Retrovirus, such as an Oncovirus, a Lentivirus or a Spumavirus. In certain embodiments, the oncovirus antigens are derived from HTLV-1, HTLV-2 or HTLV-5. In certain
 5 embodiments, the lentivirus antigens are derived from HIV-1 or HIV-2. In certain
 10 embodiments, the antigens are derived from HIV-1 subtypes (or clades), including, but
 not limited to, HIV-1 subtypes (or clades) A, B, C, D, F, G, H, J, K, O. In other
 embodiments, the antigens are derived from HIV-1 circulating recombinant forms
 (CRFs), including, but not limited to, A/B, A/E, A/G, A/G/I, etc. In certain
 15 embodiments, the retrovirus antigens are selected from gag, pol, env, tax, tat, rex, rev,
 nef, vif, vpu, and vpr. In certain embodiments, the HIV antigens are selected from gag
 (p24gag and p55gag), env (gpl60 and gp41), pol, tat, nef, rev vpu, mini-proteins,
 (preferably p55 gag and gpl40v delete). In certain embodiments, the HIV antigens are
 derived from one or more of the following strains: HIVIIIb, HIVSF2, HIVLAV,
 HIVLAI, HIVMN, HIV-1CM235, HIV-1US4, HIV-1SF162, HIV-1TV1, HIV-1MJ4.,
 20 In certain embodiments, the antigens are derived from endogenous human retroviruses,
 including, but not limited to, HERV-K ("old" HERV-K and "new" HERV-K).

Reovirus: Viral antigens include, but are not limited to, those derived from a Reovirus, such
 as an Orthoreovirus, a Rotavirus, an Orbivirus, or a Coltivirus. In certain embodiments,
 the reovirus antigens are selected from structural proteins $\lambda 1$, $\lambda 2$, $\lambda 3$, $\mu 1$, $\mu 2$, $\sigma 1$, $\sigma 2$, or
 25 $\sigma 3$, or nonstructural proteins oNS, μ NS, or ols. In certain embodiments, the reovirus
 antigens are derived from a Rotavirus. In certain embodiments, the rotavirus antigens
 are selected from VP1, VP2, VP3, VP4 (or the cleaved product VP5 and VP8), NSP 1,
 VP6, NSP3, NSP2, VP7, NSP4, or NSP5. In certain embodiments, the rotavirus
 antigens include VP4 (or the cleaved product VP5 and VP8), and VP7.

Parvovirus: Viral antigens include, but are not limited to, those derived from a Parvovirus,
 such as Parvovirus B19. In certain embodiments, the Parvovirus antigens are selected
 from VP-1, VP-2, VP-3, NS-1 and NS-2. In certain embodiments, the Parvovirus
 antigen is capsid protein VP1 or VP-2. In certain embodiments, the antigens are
 formulated into virus-like particles (VLPs).

Delta hepatitis virus (HDV): Viral antigens include, but are not limited to, those derived from
 30 HDV, particularly δ -antigen from HDV.

Hepatitis E virus (HEV): Viral antigens include, but are not limited to, those derived from
 HEV.

Hepatitis G virus (HGV): Viral antigens include, but are not limited to, those derived from
 35 HGV.

Human Herpesvirus: Viral antigens include, but are not limited to, those derived from a
 Human Herpesvirus, such as, by way of example only, Herpes Simplex Viruses (HSV),
 Varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV),

Human Herpesvirus 6 (HHV6), Human Herpesvirus 7 (HHV7), and Human Herpesvirus 8 (HHV8). In certain embodiments, the Human Herpesvirus antigens are selected from immediate early proteins (α), early proteins (β), and late proteins (γ). In certain embodiments, the HSV antigens are derived from HSV-1 or HSV-2 strains. In certain
5 embodiments, the HSV antigens are selected from glycoproteins gB, gC, gD and gH, fusion protein (gB), or immune escape proteins (gC, gE, or gI). In certain embodiments, the VZV antigens are selected from core, nucleocapsid, tegument, or envelope proteins. A live attenuated VZV vaccine is commercially available. In certain embodiments, the EBV antigens are selected from early antigen (EA) proteins, viral capsid antigen (VCA),
10 and glycoproteins of the membrane antigen (MA). In certain embodiments, the CMV antigens are selected from capsid proteins, envelope glycoproteins (such as gB and gH), and tegument proteins. In other embodiments, CMV antigens may be selected from one or more of the following proteins: pp65, IE1, gB, gD, gH, gL, gM, gN, gO, UL128, UL129, gUL130, UL150, UL131, UL33, UL78, US27, US28, RL5A, RL6, RL10, RL11,
15 RL12, RL13, UL1, UL2, UL4, UL5, UL6, UL7, UL8, UL9, UL10, UL11, UL14, UL15A, UL16, UL17, UL18, UL22A, UL38, UL40, UL41A, UL42, UL116, UL119, UL120, UL121, UL124, UL132, UL147A, UL148, UL142, UL144, UL141, UL140, UL135, UL136, UL138, UL139, UL133, UL135, UL148A, UL148B, UL148C, UL148D, US2, US3, US6, US7, US8, US9, US10, US11, US12, US13, US14, US15, US16, US17, US18, US19, US20, US21, US29, US30 and US34A. CMV antigens may also be fusions of one or more CMV proteins, such as, by way of example only, pp65/IE1 (Reap *et al*, *Vaccine* (2007) 25:7441-7449). In certain embodiments, the antigens are formulated into virus-like particles (VLPs).

Papovaviruses: Antigens include, but are not limited to, those derived from Papovaviruses,
25 such as Papillomaviruses and Polyomaviruses. In certain embodiments, the Papillomaviruses include HPV serotypes 1, 2, 4, 5, 6, 8, 11, 13, 16, 18, 31, 33, 35, 39, 41, 42, 47, 51, 57, 58, 63 and 65. In certain embodiments, the HPV antigens are derived from serotypes 6, 11, 16 or 18. In certain embodiments, the HPV antigens are selected from capsid proteins (L1) and (L2), or E1 - E7, or fusions thereof. In certain
30 embodiments, the HPV antigens are formulated into virus-like particles (VLPs). In certain embodiments, the Polyomyavirus viruses include BK virus and JK virus. In certain embodiments, the Polyomavirus antigens are selected from VP1, VP2 or VP3.

Adenovirus: Antigens include those derived from Adenovirus. In certain embodiments, the Adenovirus antigens are derived from Adenovirus serotype 36 (Ad-36). In certain
35 embodiments, the antigen is derived from a protein or peptide sequence encoding an Ad-36 coat protein or fragment thereof (WO 2007/120362).

Further provided are antigens, compositions, methods, and microbes included in *Vaccines*, 4th Edition (Plotkin and Orenstein ed. 2004); *Medical Microbiology* 4th Edition (Murray et al. ed. 2002); *Virology*, 3rd Edition (W.K. Joklik ed. 1988); *Fundamental Virology*, 2nd Edition (B.N. Fields and

D.M. Knipe, eds. 1991), which are contemplated in conjunction with the immunogenic compositions provided herein.

In a preferred embodiment, the immunogen may elicit an immune response against an influenza virus, including influenza A and B viruses. Various forms of influenza virus immunogen are currently available, typically based either on live virus or on inactivated virus. Inactivated vaccines may be based on whole virions, split virions, or on purified surface antigens. Influenza immunogens can also be presented in the form of virosomes. Hemagglutinin is the main immunogen in current inactivated vaccines, and vaccine doses are standardised by reference to HA levels, typically measured by SRID. Existing vaccines typically contain about 15µg of HA per strain, although lower doses can be used *e.g.* for children, or in pandemic situations, or when using an adjuvant. Fractional doses such as ½ (*i.e.* 7.5µg HA per strain), ¼ and 1/8 have been used, as have higher doses (*e.g.* 3x or 9x doses [72,73]). Thus compositions may include between 0.1 and 150µg of HA per influenza strain, preferably between 0.1 and 50µg *e.g.* 0.1-20µg, 0.1-15µg, 0.1-10µg, 0.1-7.5µg, 0.5µg, *etc.* Particular doses include *e.g.* about 45, about 30, about 15, about 10, about 7.5, about 5, about 3.8, about 3.75, about 1.9, about 1.5, *etc.* per strain. It is usual to include substantially the same mass of HA for each strain included in the vaccine *e.g.* such that the HA mass for each strain is within 10% of the mean HA mass per strain, and preferably within 5% of the mean. For live vaccines, dosing is measured by median tissue culture infectious dose (TCID₅₀) rather than HA content, and a TCID₅₀ of between 10⁶ and 10⁸ (preferably between 10^{6.5}-10^{7.5}) per strain is typical. Rather than use SPF eggs as the substrate for viral growth, where virus is harvested from infected allantoic fluids of hens' eggs, cell lines that support influenza virus replication may be used. The cell line will typically be of mammalian origin *e.g.* MDCK. Influenza A virus immunogens may be from any suitable HA subtype strain *e.g.* H1, H3, H5, H7, H9 *etc.*, such as a H1N1, H3N2 and/or H5N1 strain.

Bacterial Antigens

Bacterial antigens suitable for use in immunogenic compositions provided herein include, but are not limited to, proteins, polysaccharides, lipopolysaccharides, polynucleotides, and outer membrane vesicles which are isolated, purified or derived from a bacteria. In certain embodiments, the bacterial antigens include bacterial lysates and inactivated bacteria formulations. In certain embodiments, the bacterial antigens are produced by recombinant expression. In certain embodiments, the bacterial antigens include epitopes which are exposed on the surface of the bacteria during at least one stage of its life cycle. Bacterial antigens are preferably conserved across multiple serotypes. In certain embodiments, the bacterial antigens include antigens derived from one or more of the bacteria set forth below as well as the specific antigens examples identified below:

Neisseria meningitidis: *N.meningitidis* antigens include, but are not limited to, proteins, saccharides (including a polysaccharide, or lipooligosaccharide), or outer-membrane vesicles purified or derived from *N. meningitidis* serogroup such as A, C, W135, Y, X or B. A useful combination of *N.meningitidis* protein antigens includes including one, two or three of a NHBA, a fHbp, and/or a NadA immunogen *e.g.* the mixture disclosed in

reference 74.

Streptococcus pneumoniae: *Streptococcus pneumoniae* antigens include, but are not limited to, a saccharide (including a polysaccharide or an oligosaccharide) and/or protein from *Streptococcus pneumoniae*. The saccharide may be a polysaccharide having the size that arises during purification of the saccharide from bacteria, or it may be an oligosaccharide achieved by fragmentation of such a polysaccharide. In the 7-valent PREVNAR™ product, for instance, 6 of the saccharides are presented as intact polysaccharides while one (the 18C serotype) is presented as an oligosaccharide. In certain embodiments saccharide antigens are selected from one or more of the following pneumococcal serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and/or 33F. An immunogenic composition may include multiple serotypes e.g. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or more serotypes. 7-valent, 9-valent, 10-valent, 11-valent and 13-valent conjugate combinations are already known in the art, as is a 23-valent unconjugated combination. For example, an 10-valent combination may include saccharide from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. An 11-valent combination may further include saccharide from serotype 3. A 12-valent combination may add to the 10-valent mixture: serotypes 6A and 19A; 6A and 22F; 19A and 22F; 6A and 15B; 19A and 15B; r 22F and 15B; A 13-valent combination may add to the 11-valent mixture: serotypes 19A and 22F; 8 and 12F; 8 and 15B; 8 and 19A; 8 and 22F; 12F and 15B; 12F and 19A; 12F and 22F; 15B and 19A; 15B and 22F. etc. In certain embodiments, protein antigens may be selected from a protein identified in W098/18931, WO98/18930, US Patent 6,699,703, US Patent 6,800,744, WO97/43303, WO97/37026, WO 02/079241, WO 02/34773, WO 00/06737, WO 00/06738, WO 00/58475, WO 2003/082183, WO 00/37105, WO 02/22167, WO 02/22168, WO 2003/104272, WO 02/08426, WO 01/12219, WO 99/53940, WO 01/81380, WO 2004/092209, WO 00/76540, WO 2007/116322, LeMieux *et al*, Infect. Imm. (2006) 74:2453-2456, Hoskins *et al*, J. Bacteriol. (2001) 183:5709-5717, Adamou *et al*, Infect. Immun. (2001) 69(2):949-958, Briles *et al*, J. Infect. Dis. (2000) 182:1694-1701, Talkington *et al*, Microb. Pathog. (1996) 21(1):17-22, Bethe *et al*, FEMS Microbiol. Lett. (2001) 205(1):99-104, Brown *et al*, Infect. Immun. (2001) 69:6702-6706, Whalen *et al*, FEMS Immunol. Med. Microbiol. (2005) 43:73-80, Jomaa *et al*, Vaccine (2006) 24(24):5133-5139. In other embodiments, *Streptococcus pneumoniae* proteins may be selected from the Poly Histidine Triad family (PhtX), the Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins, pneumolysin (Ply), PspA, PsaA, Spl28, SplIOL, Spl30, Spl25, Spl33, pneumococcal pilus subunits.

Streptococcus pyogenes (Group A *Streptococcus*): Group A *Streptococcus* antigens include, but are not limited to, a protein identified in WO 02/34771 or WO 2005/032582 (including GAS 40), fusions of fragments of GAS M proteins (including those described

in WO 02/094851, and Dale, Vaccine (1999) 17:193-200, and Dale, Vaccine 14(10): 944-948), fibronectin binding protein (Sfbl), Streptococcal heme-associated protein (Shp), and Streptolysin S (SagA).

5 *Moraxella catarrhalis*: *Moraxella* antigens include, but are not limited to, antigens identified in WO 02/18595 and WO 99/58562, outer membrane protein antigens (HMW-OMP), C-antigen, and/or LPS.

Bordetella pertussis: Pertussis antigens include, but are not limited to, pertussis toxoid (PT) and filamentous haemagglutinin (FHA) from *B. pertussis*, optionally also combination with pertactin and/or agglutinogens 2 and 3.

10 *Burkholderia*: Burkholderia antigens include, but are not limited to Burkholderia mallei, Burkholderia pseudomallei and Burkholderia cepacia.

Staphylococcus aureus: Staph aureus antigens include, but are not limited to, a polysaccharide and/or protein from *S. aureus*. *S. aureus* polysaccharides include, but are not limited to, type 5 and type 8 capsular polysaccharides (CP5 and CP8) optionally conjugated to nontoxic recombinant *Pseudomonas aeruginosa* exotoxin A, such as StaphVAX™, type 336 polysaccharides (336PS), polysaccharide intercellular adhesions (PIA, also known as PNAG). *S. aureus* proteins include, but are not limited to, antigens derived from surface proteins, invasins (leukocidin, kinases, hyaluronidase), surface factors that inhibit phagocytic engulfment (capsule, Protein A), carotenoids, catalase production, Protein A, coagulase, clotting factor, and/or membrane-damaging toxins (optionally detoxified) that lyse eukaryotic cell membranes (hemolysins, leukotoxin, leukocidin). In certain embodiments, *S. aureus* antigens may be selected from a protein identified in WO 02/094868, WO 2008/019162, WO 02/059148, WO 02/102829, WO 03/011899, WO 2005/079315, WO 02/077183, WO 99/27109, WO 01/70955, WO 00/12689, WO 00/12131, WO 2006/032475, WO 2006/032472, WO 2006/032500, WO 25 2007/113222, WO 2007/113223, WO 2007/113224. In other embodiments, *S. aureus* antigens may be selected from IsdA, IsdB, IsdC, SdrC, SdrD, SdrE, ClfA, ClfB, SasF, SasD, SasH (AdsA), Spa, EsaC, EsxA, EsxB, Emp, HlaH35L, CP5, CP8, PNAG, 336PS.

30 *Staphylococcus epidermis*: *S. epidermidis* antigens include, but are not limited to, slime-associated antigen (SAA).

Clostridium tetani (Tetanus): Tetanus antigens include, but are not limited to, tetanus toxoid (TT). In certain embodiments such antigens are used as a carrier protein in conjunction/conjugated with the immunogenic compositions provided herein.

35 *Clostridium perfringens*: Antigens include, but are not limited to, Epsilon toxin from *Clostridium perfringens*.

Clostridium botulinum (Botulism): Botulism antigens include, but are not limited to, those derived from *C. botulinum*.

Cornynebacterium diphtheriae (Diphtheria): Diphtheria antigens include, but are not limited

to, diphtheria toxin, preferably detoxified, such as CRM197. Additionally antigens capable of modulating, inhibiting or associated with ADP ribosylation are contemplated for combination/co-administration/conjugation with the immunogenic compositions provided herein. In certain embodiments, the diphtheria toxoids are used as carrier proteins.

Haemophilus influenzae B (Hib): Hib antigens include, but are not limited to, a Hib saccharide antigen. The Hib antigens may be conjugated.

Pseudomonas aeruginosa: Pseudomonas antigens include, but are not limited to, endotoxin A, Wzz protein, *P. aeruginosa* LPS, LPS isolated from PAOI (05 serotype), and/or Outer Membrane Proteins, including Outer Membrane Proteins F (OprF).

Brucella. Bacterial antigens derived from *Brucella*, including but not limited to, *B. abortus*, *B. canis*, *B. melitensis*, *B. neotomae*, *B. ovis*, *B. suis* and *B. pinnipediae*.

Francisella. Bacterial antigens derived from *Francisella*, including but not limited to, *F. novicida*, *F. philomiragia* and *F. tularensis*.

Streptococcus agalactiae (Group B Streptococcus): Group B Streptococcus antigens include, but are not limited to, a protein or saccharide antigen identified in WO 02/34771, WO 03/093306, WO 04/041 157, or WO 2005/002619 (including proteins GBS 80, GBS 104, GBS 276 and GBS 322, and including saccharide antigens derived from serotypes Ia, Ib, Ia/c, II, III, IV, V, VI, VII and VIII).

Neisseria gonorrhoeae: Gonorrhoeae antigens include, but are not limited to, Por (or porin) protein, such as PorB (see Zhu *et al.*, *Vaccine* (2004) 22:660 - 669), a transferring binding protein, such as TbpA and TbpB (See Price *et al.*, *Infection and Immunity* (2004) 71(1):277 - 283), a opacity protein (such as Opa), a reduction-modifiable protein (Rmp), and outer membrane vesicle (OMV) preparations (see Plante *et al.*, *J Infectious Disease* (2000) 182:848 - 855), also see, *e.g.*, W099/24578, W099/36544, W099/57280, WO02/079243).

Chlamydia trachomatis: *Chlamydia trachomatis* antigens include, but are not limited to, antigens derived from serotypes A, B, Ba and C (agents of trachoma, a cause of blindness), serotypes LI, L2 & L3 (associated with Lymphogranuloma venereum), and serotypes, D-K. In certain embodiments, *chlamydia trachomatis* antigens include, but are not limited to, an antigen identified in WO 00/37494, WO 03/049762, WO 03/068811, or WO 05/002619, including PepA (CT045), LcrE (CT089), ArtJ (CT381), DnaK (CT396), CT398, OmpH-like (CT242), L7/L12 (CT316), OmcA (CT444), AtosS (CT467), CT547, Eno (CT587), HrtA (CT823), and MurG (CT761).

Treponema pallidum (Syphilis): Syphilis antigens include, but are not limited to, TmpA antigen.

Haemophilus ducreyi (causing chancroid): *Ducreyi* antigens include, but are not limited to, outer membrane protein (DsrA).

Enterococcus faecalis or *Enterococcus faecium*: Antigens include, but are not limited to, a trisaccharide repeat or other *Enterococcus* derived antigens.

Helicobacter pylori: *H. pylori* antigens include, but are not limited to, CagA, VacA, NAP, HopX, HopY and/or urease antigen.

5 *Staphylococcus saprophyticus*: Antigens include, but are not limited to, the 160 kDa hemagglutinin of *S. saprophyticus* antigen.

Yersinia enterocolitica Antigens include, but are not limited to, LPS.

10 *E. coli*: *E. coli* antigens may be derived from enterotoxigenic *E. coli* (EPEC), enteroaggregative *E. coli* (EAaggEC), diffusely adhering *E. coli* (DAEC), enteropathogenic *E. coli* (EPEC), extraintestinal pathogenic *E. coli* (ExPEC) and/or enterohemorrhagic *E. coli* (EHEC). ExPEC antigens include, but are not limited to, accessory colonization factor (orf526), orf353, bacterial Ig-like domain (group 1) protein (orf405), orf1364, NodT-family outer-membrane-factor-lipoprotein efflux transporter (orf1767), gspK (orf515), gspJ (orf516), tonB-dependent siderophore receptor (orf597), fimbrial protein (orf613), upec-948, upec-1232, A chain precursor of the type-1 fimbrial protein (upec-1875), yap H homolog (upec-2820), and hemolysin A (recp-3768).

20 *Bacillus anthracis* (anthrax): *B. anthracis* antigens include, but are not limited to, A-components (lethal factor (LF) and edema factor (EF)), both of which can share a common B-component known as protective antigen (PA). In certain embodiments, *B. anthracis* antigens are optionally detoxified.

Yersinia pestis (plague): Plague antigens include, but are not limited to, F1 capsular antigen, LPS, *Yersinia pestis* V antigen.

25 *Mycobacterium tuberculosis*: Tuberculosis antigens include, but are not limited to, lipoproteins, LPS, BCG antigens, a fusion protein of antigen 85B (Ag85B), ESAT-6 optionally formulated in cationic lipid vesicles, *Mycobacterium tuberculosis* (Mtb) isocitrate dehydrogenase associated antigens, and MPT51 antigens.

Rickettsia: Antigens include, but are not limited to, outer membrane proteins, including the outer membrane protein A and/or B (OmpB), LPS, and surface protein antigen (SPA).

30 *Listeria monocytogenes*: Bacterial antigens include, but are not limited to, those derived from *Listeria monocytogenes*.

Chlamydia pneumoniae: Antigens include, but are not limited to, those identified in WO 02/02606.

35 *Vibrio cholerae*: Antigens include, but are not limited to, proteinase antigens, LPS, particularly lipopolysaccharides of *Vibrio cholerae* II, 01 Inaba O-specific polysaccharides, *V. cholera* 0139, antigens of IEM108 vaccine and Zonula occludens toxin (Zot).

Salmonella typhi (typhoid fever): Antigens include, but are not limited to, capsular polysaccharides preferably conjugates (Vi, i.e. vax-TyVi).

5 *Borrelia burgdorferi* (Lyme disease): Antigens include, but are not limited to, lipoproteins (such as OspA, OspB, Osp C and Osp D), other surface proteins such as OspE-related proteins (Erps), decorin-binding proteins (such as DbpA), and antigenically variable VI proteins, such as antigens associated with P39 and PI3 (an integral membrane protein, VlsE Antigenic Variation Protein).

Porphyromonas gingivalis: Antigens include, but are not limited to, *P. gingivalis* outer membrane protein (OMP).

10 *Klebsiella*: Antigens include, but are not limited to, an OMP, including OMP A, or a polysaccharide optionally conjugated to tetanus toxoid.

Other bacterial antigens used in the immunogenic compositions provided herein include, but are not limited to, capsular antigens, polysaccharide antigens, protein antigens or polynucleotide antigens of any of the above. Other bacterial antigens used in the immunogenic compositions provided herein
15 include, but are not limited to, an outer membrane vesicle (OMV) preparation. Additionally, other bacterial antigens used in the immunogenic compositions provided herein include, but are not limited to, live, attenuated, and/or purified versions of any of the aforementioned bacteria. In certain embodiments, the bacterial antigens used in the immunogenic compositions provided herein are derived from gram-negative bacteria, while in other embodiments they are derived from gram-
20 positive bacteria. In certain embodiments, the bacterial antigens used in the immunogenic compositions provided herein are derived from aerobic bacteria, while in other embodiments they are derived from anaerobic bacteria.

In certain embodiments, any of the above bacterial-derived saccharides (polysaccharides, LPS, LOS or oligosaccharides) are conjugated to another agent or antigen, such as a carrier protein (for example
25 CRM₁₉₇). In certain embodiments, such conjugations are direct conjugations effected by reductive amination of carbonyl moieties on the saccharide to amino groups on the protein. In other embodiments, the saccharides are conjugated through a linker, such as, with succinamide or other linkages provided in *Bioconjugate Techniques*, 1996 and *CRC, Chemistry of Protein Conjugation and Cross-Linking*, 1993.

30 Fungal Antigens

Fungal antigens for use in the immunogenic compositions provided herein include, but are not limited to, those derived from one or more of the fungi set forth below.

Fungal antigens are derived from Dermatophytes, including: Epidermophyton floccosum, Microsporum audouini, Microsporum canis, Microsporum distortum, Microsporum
35 equinum, Microsporum gypsum, Microsporum nanum, Trichophyton concentricum, Trichophyton equinum, Trichophyton gallinae, Trichophyton gypseum, Trichophyton megnini, Trichophyton mentagrophytes, Trichophyton quinckeanum, Trichophyton rubrum, Trichophyton schoenleini, Trichophyton tonsurans, Trichophyton verrucosum,

T. verrucosum var. album, var. discoides, var. ochraceum, Trichophyton violaceum, and/or Trichophyton faviforme; and

Fungal pathogens are derived from Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus, Aspergillus sydowi, Aspergillus flavarus, Aspergillus glaucus, Blastoschizomyces capitatus, Candida albicans, Candida enolase, Candida tropicalis, Candida glabrata, Candida krusei, Candida parapsilosis, Candida stellatoidea, Candida kusei, Candida parakwsei, Candida lusitaniae, Candida pseudotropicalis, Candida guilliermondi, Cladosporium carrionii, Coccidioides immitis, Blastomyces dermatidis, Cryptococcus neoformans, Geotrichum clavatum, Histoplasma capsulatum, Klebsiella pneumoniae, Microsporidia, Encephalitozoon spp., Septata intestinalis and Enterocytozoon bienewisi; the less common are Brachiola spp, Microsporidium spp., Nosema spp., Pleistophora spp., Trachipleistophora spp., Vittiforma spp Paracoccidioides brasiliensis, Pneumocystis carinii, Pythium insidiosum, Pityrosporum ovale, Saccharomyces cerevisiae, Saccharomyces boulardii, Saccharomyces pombe, Scedosporium apiosperum, Sporothrix schenckii, Trichosporon beigeli, Toxoplasma gondii, Penicillium marneffeii, Malassezia spp., Fonsecaea spp., Wangiella spp., Sporothrix spp., Basidiobolus spp., Conidiobolus spp., Rhizopus spp, Mucor spp, Absidia spp, Mortierella spp, Cunninghamella spp, Saksenaea spp., Alternaria spp, Curvularia spp, Helminthosporium spp, Fusarium spp, Aspergillus spp, Penicillium spp, Monolinia spp, Rhizoctonia spp, Paecilomyces spp, Pithomyces spp, and Cladosporium spp.

In certain embodiments, the process for producing a fungal antigen includes a method wherein a solubilized fraction extracted and separated from an insoluble fraction obtainable from fungal cells of which cell wall has been substantially removed or at least partially removed, characterized in that the process comprises the steps of: obtaining living fungal cells; obtaining fungal cells of which cell wall has been substantially removed or at least partially removed; bursting the fungal cells of which cell wall has been substantially removed or at least partially removed; obtaining an insoluble fraction; and extracting and separating a solubilized fraction from the insoluble fraction.

For example, the immunogen may elicit an immune response against a Candida fungus such as C.albicans. For instance, the immunogen may be a β -glucan, which may be conjugated to a carrier protein. The glucan may include β -1,3 and/or β -1,6 linkages. Suitable immunogens include those disclosed in references 75 & 76. STD Antigens

In certain embodiments, the immunogenic compositions provided herein include one or more antigens derived from a sexually transmitted disease (STD). In certain embodiments, such antigens provide for prophylaxis for STD's such as chlamydia, genital herpes, hepatitis (such as HCV), genital warts, gonorrhea, syphilis and/or chancroid. In other embodiments, such antigens provide for therapy for STD's such as chlamydia, genital herpes, hepatitis (such as HCV), genital warts, gonorrhea, syphilis and/or chancroid. Such antigens are derived from one or more viral or bacterial

STD's. In certain embodiments, the viral STD antigens are derived from HIV, herpes simplex virus (HSV-1 and HSV-2), human papillomavirus (HPV), and hepatitis (HCV). In certain embodiments, the bacterial STD antigens are derived from *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Treponema pallidum*, *Haemophilus ducreyi*, *E. coli*, and *Streptococcus agalactiae*. Examples of specific antigens derived from these pathogens are described above.

Respiratory Antigens

In certain embodiments, the immunogenic compositions provided herein include one or more antigens derived from a pathogen which causes respiratory disease. By way of example only, such respiratory antigens are derived from a respiratory virus such as Orthomyxoviruses (influenza), Pneumovirus (RSV), Paramyxovirus (PIV), Morbillivirus (measles), Togavirus (Rubella), VZV, and Coronavirus (SARS). In certain embodiments, the respiratory antigens are derived from a bacteria which causes respiratory disease, such as, by way of example only, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Bordetella pertussis*, *Mycobacterium tuberculosis*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Bacillus anthracis*, and *Moraxella catarrhalis*. Examples of specific antigens derived from these pathogens are described above.

Pediatric Vaccine Antigens

In certain embodiments, the immunogenic compositions provided herein include one or more antigens suitable for use in pediatric subjects. Pediatric subjects are typically less than about 3 years old, or less than about 2 years old, or less than about 1 years old. Pediatric antigens are administered multiple times over the course of 6 months, 1, 2 or 3 years. Pediatric antigens are derived from a virus which may target pediatric populations and/or a virus from which pediatric populations are susceptible to infection. Pediatric viral antigens include, but are not limited to, antigens derived from one or more of influenza, Mumps, measles, Rubella, polio and HBV. Paediatric bacterial antigens include antigens derived from one or more of *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Bordetella pertussis*, *Clostridium tetani* (Tetanus), *Corynebacterium diphtheriae* (Diphtheria[^] and *Haemophilus influenzae B* (Rib). Examples of specific antigens derived from these pathogens are described above.

Antigens suitable for use in Elderly or Immunocompromised Individuals

In certain embodiments, the immunogenic compositions provided herein include one or more antigens suitable for use in elderly or immunocompromised individuals. Such individuals may need to be vaccinated more frequently, with higher doses or with adjuvanted formulations to improve their immune response to the targeted antigens. Antigens which are targeted for use in Elderly or Immunocompromised individuals include antigens derived from one or more of the following pathogens: *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes* (Group A *Streptococcus*), *Moraxella catarrhalis*, *Bordetella pertussis*, *Staphylococcus aureus*, *Staphylococcus epidermis*, *Clostridium tetani* (Tetanus), *Corynebacterium diphtheriae* (Diphtheria), *Haemophilus influenzae B* (Hib), *Pseudomonas aeruginosa*, *Legionella pneumophila*, *Streptococcus agalactiae* (Group B *Streptococcus*), *Enterococcus faecalis*, *Helicobacter pylori*, *Chlamydia pneumoniae*,

Orthomyxovirus (influenza), Pneumovirus (RSV), Paramyxovirus (PIV and Mumps), Morbillivirus (measles), Togavirus (Rubella), Enterovirus (polio), HBV, Coronavirus (SARS), Varicella-zoster virus (VZV), Epstein Barr virus (EBV), Cytomegalovirus (CMV). Examples of specific antigens derived from these pathogens are described above.

5 Antigens suitable for use in Adolescent Vaccines

In certain embodiments, the immunogenic compositions provided herein include one or more antigens suitable for use in adolescent subjects. Adolescents are in need of a boost of a previously administered pediatric antigen. Pediatric antigens which are suitable for use in adolescents are described above. In addition, adolescents are targeted to receive antigens derived from an STD
10 pathogen in order to ensure protective or therapeutic immunity before the beginning of sexual activity. STD antigens which are suitable for use in adolescents are described above.

Tumor Antigens

In certain embodiments, a tumor antigen or cancer antigen is used in conjunction with the immunogenic compositions provided herein. In certain embodiments, the tumor antigens is a peptide-
15 containing tumor antigens, such as a polypeptide tumor antigen or glycoprotein tumor antigens. In certain embodiments, the tumor antigen is a saccharide-containing tumor antigen, such as a glycolipid tumor antigen or a ganglioside tumor antigen. In certain embodiments, the tumor antigen is a polynucleotide-containing tumor antigen that expresses a polypeptide-containing tumor antigen, for instance, an RNA vector construct or a DNA vector construct, such as plasmid DNA.

20 Tumor antigens appropriate for the use in conjunction with the immunogenic compositions provided herein encompass a wide variety of molecules, such as (a) polypeptide-containing tumor antigens, including polypeptides (which can range, for example, from 8-20 amino acids in length, although lengths outside this range are also common), lipopolypeptides and glycoproteins, (b) saccharide-containing tumor antigens, including poly-saccharides, mucins, gangliosides, glycolipids and
25 glycoproteins, and (c) polynucleotides that express antigenic polypeptides.

In certain embodiments, the tumor antigens are, for example, (a) full length molecules associated with cancer cells, (b) homologs and modified forms of the same, including molecules with deleted, added and/or substituted portions, and (c) fragments of the same. In certain embodiments, the tumor antigens are provided in recombinant form. In certain embodiments, the tumor antigens include, for
30 example, class I-restricted antigens recognized by CD8+ lymphocytes or class II-restricted antigens recognized by CD4+ lymphocytes.

In certain embodiments, the tumor antigens include, but are not limited to, (a) cancer-testis antigens such as NY-ESO-1, SSX2, SCP1 as well as RAGE, BAGE, GAGE and MAGE family polypeptides, for example, GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and
35 MAGE-12 (which can be used, for example, to address melanoma, lung, head and neck, NSCLC, breast, gastrointestinal, and bladder tumors), (b) mutated antigens, for example, p53 (associated with various solid tumors, e.g., colorectal, lung, head and neck cancer), p21/Ras (associated with, e.g., melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, e.g., melanoma),

MUM1 (associated with, e.g., melanoma), caspase-8 (associated with, e.g., head and neck cancer), CIA 0205 (associated with, e.g., bladder cancer), HLA-A2-R1701, beta catenin (associated with, e.g., melanoma), TCR (associated with, e.g., T-cell non-Hodgkins lymphoma), BCR-abl (associated with, e.g., chronic myelogenous leukemia), triosephosphate isomerase, KIA 0205, CDC-27, and LDLR-FUT, (c) over-expressed antigens, for example, Galectin 4 (associated with, e.g., colorectal cancer), Galectin 9 (associated with, e.g., Hodgkin's disease), proteinase 3 (associated with, e.g., chronic myelogenous leukemia), WT 1 (associated with, e.g., various leukemias), carbonic anhydrase (associated with, e.g., renal cancer), aldolase A (associated with, e.g., lung cancer), PRAME (associated with, e.g., melanoma), HER-2/neu (associated with, e.g., breast, colon, lung and ovarian cancer), alpha-fetoprotein (associated with, e.g., hepatoma), KSA (associated with, e.g., colorectal cancer), gastrin (associated with, e.g., pancreatic and gastric cancer), telomerase catalytic protein, MUC-1 (associated with, e.g., breast and ovarian cancer), G-250 (associated with, e.g., renal cell carcinoma), p53 (associated with, e.g., breast, colon cancer), and carcinoembryonic antigen (associated with, e.g., breast cancer, lung cancer, and cancers of the gastrointestinal tract such as colorectal cancer), (d) shared antigens, for example, melanoma-melanocyte differentiation antigens such as MART-1/Melan A, gp100, MC1R, melanocyte-stimulating hormone receptor, tyrosinase, tyrosinase related protein-1/TRP1 and tyrosinase related protein-2/TRP2 (associated with, e.g., melanoma), (e) prostate associated antigens such as PAP, PSA, PSMA, PSH-P1, PSM-P1, PSM-P2, associated with e.g., prostate cancer, (f) immunoglobulin idiotypes (associated with myeloma and B cell lymphomas, for example), and (g) other tumor antigens, such as polypeptide- and saccharide-containing antigens including (i) glycoproteins such as sialyl Tn and sialyl Le^x (associated with, e.g., breast and colorectal cancer) as well as various mucins; glycoproteins are coupled to a carrier protein (e.g., MUC-1 are coupled to KLH); (ii) lipopolypeptides (e.g., MUC-1 linked to a lipid moiety); (iii) polysaccharides (e.g., Globo H synthetic hexasaccharide), which are coupled to a carrier proteins (e.g., to KLH), (iv) gangliosides such as GM2, GM12, GD2, GD3 (associated with, e.g., brain, lung cancer, melanoma), which also are coupled to carrier proteins (e.g., KLH).

In certain embodiments, the tumor antigens include, but are not limited to, p15, Hom/Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein Barr virus antigens, EBNA, human papillomavirus (HPV) antigens, including E6 and E7, hepatitis B and C virus antigens, human T-cell lymphotropic virus antigens, TSP-180, pl85erbB2, pl80erbB-3, c-met, mn-23Hl, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, pl6, TAGE, PSCA, CT7, 43-9F, 5T4, 791 Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 (Mac-2 binding protein\cyclophilin C-associated protein), TAAL6, TAG72, TLP, TPS, and the like.

Polynucleotide-containing antigens used in conjunction with the immunogenic compositions provided herein include polynucleotides that encode polypeptide cancer antigens such as those listed above. In certain embodiments, the polynucleotide-containing antigens include, but are not limited

to, DNA or RNA vector constructs, such as plasmid vectors (e.g., pCMV), which are capable of expressing polypeptide cancer antigens *in vivo*.

In certain embodiments, the tumor antigens are derived from mutated or altered cellular components. After alteration, the cellular components no longer perform their regulatory functions, and hence the cell may experience uncontrolled growth. Representative examples of altered cellular components include, but are not limited to ras, p53, Rb, altered protein encoded by the Wilms' tumor gene, ubiquitin, mucin, protein encoded by the DCC, APC, and MCC genes, as well as receptors or receptor-like structures such as neu, thyroid hormone receptor, platelet derived growth factor (PDGF) receptor, insulin receptor, epidermal growth factor (EGF) receptor, and the colony stimulating factor (CSF) receptor.

Various other immunogens may be used.

Carrier Moieties

Saccharide antigens may be conjugated to a carrier moiety.

The carrier moiety may be a protein. Typical carrier proteins are bacterial toxins, such as diphtheria or tetanus toxins, or toxoids or mutants or fragments thereof. The CRM 197 diphtheria toxin mutant [77] is useful. Other suitable carrier proteins include the *N.meningitidis* outer membrane protein complex [78], synthetic peptides [79,80], heat shock proteins [81,82], pertussis proteins [83,84], cytokines [85], lymphokines [85], hormones [85], growth factors [85], artificial proteins comprising multiple human CD4⁺ T cell epitopes from various pathogen-derived antigens [86] such as N19 [87], protein D from *H.influenzae* [88-90], pneumolysin [91] or its non-toxic derivatives [92], pneumococcal surface protein PspA [93], iron-uptake proteins [94], toxin A or B from *C.difficile* [95], recombinant *P.aeruginosa* exoprotein A (rEPA) [96], *etc.* In some embodiments the carrier protein is a *S.aureus* protein, such as an antigen selected from the first, second, third or fourth antigen groups.

Where a composition includes more than one immunogen, each immunogen may use the same carrier protein or a different carrier protein.

Conjugates may have excess carrier (w/w) or excess antigen (w/w). In some embodiments, a conjugate may include substantially equal weights of each.

The carrier molecule may be covalently conjugated to the carrier directly or via a linker. Direct linkages to the protein may be achieved by, for instance, reductive amination between the antigen and the carrier, as described in, for example, references 97 and 98. The antigen may first need to be activated *e.g.* by oxidation. Linkages via a linker group may be made using any known procedure, for example, the procedures described in references 99 and 100. A preferred type of linkage is an adipic acid linker, which may be formed by coupling a free -NH₂ group (*e.g.* introduced to a glucan by amination) with adipic acid (using, for example, diimide activation), and then coupling a protein to the resulting antigen-adipic acid intermediate [101,102]. Another preferred type of linkage is a carbonyl linker, which may be formed by reaction of a free hydroxyl group of a saccharide CDI [103,

104] followed by reaction with a protein to form a carbamate linkage. Other linkers include β -propionamido [105], nitrophenyl-ethylamine [106], haloacyl halides [107], glycosidic linkages [108], 6-aminocaproic acid [109], ADH [110], C₄ to C₁₂ moieties [111], *etc.* Carbodiimide condensation can also be used [112].

5 ***Further non-active components***

Compositions of the invention can include components in addition to the immunogen, TLR agonist, and needle material *e.g.* they typically include one or more pharmaceutical carrier(s) and/or excipient(s). A thorough discussion of such components is available in reference 113. These components may be added to facilitate the solid nature of the composition, or may be residual from
10 the earlier aqueous nature of a component.

Compositions may include one or more preservatives, such as thiomersal or 2-phenoxyethanol. Mercury-free compositions are preferred, and preservative-free vaccines can be prepared.

Compositions can include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is typical, which may be present at between 1 and 20 mg/ml *e.g.* 10 \pm 2 mg/ml or 9 mg/ml. Other salts
15 that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, *etc.* Compositions used for intradermal delivery preferably do not include aluminium salts such as aluminium phosphate and aluminium hydroxide.

Compositions may include one or more buffer salts. Buffering salts may be added to provide
20 buffering when the composition is redissolved. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer. Buffer salts will typically be included in the 5-20mM range. If a phosphate buffer is used then the concentration of phosphate ions should, in some embodiments, be <50mM (see above) *e.g.* <10mM.

Compositions typically have a pH between 5.0 and 9.5 *e.g.* between 6.0 and 8.0. The pH of solid
25 compositions is the pH of the composition when re-dissolved in water.

Compositions are preferably sterile, non-pyrogenic (*e.g.* containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose), and/or gluten-free.

Compositions are suitable for administration to animal (and, in particular, human) patients, and thus include both human and veterinary uses. They may be used in a method of raising an immune
30 response in a patient, comprising the step of administering the composition to the patient. Compositions may be administered before a subject is exposed to a pathogen and/or after a subject is exposed to a pathogen. A composition is administered by applying it to the skin of a subject.

The invention also provides a hermetically sealed container containing a composition of the invention. Suitable containers include *e.g.* a pouch or envelope.

Dosing

The total dose of immunogen in a skin patch may be 10^{μg}/patch-100^{μg}/patch. The total dose may be 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100^{μg}/patch. The particular dose used is dependent on the particular immunogen and the particular TLR agonist used.

5 Intradermal administration may allow lower doses of immunogen and TLR agonist to be used in comparison to those required for intramuscular administration.

The total dose of TLR agonist provided in a skin patch may be 10^{μg}/patch-100^{μg}/patch. The total dose may be 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100^{μg}/patch. The particular dose used is dependent on the particular immunogen and the particular TLR agonist used.

10 Intradermal administration may allow lower doses of immunogen and TLR agonist to be used in comparison to those required for intramuscular administration.

The ratio of antigen to TLR agonist (by mass) may be around 10:1.

Immunogen concentration

15 Immunogenic compositions delivered intradermally by microneedles may require much lower volumes than the typical immunogenic compositions delivered intramuscularly, but they may require the same amount of antigen, which will often require a more concentrated bulk antigen.

Various techniques can be used for this concentration step including, but not limited to: centrifugal filtration; ultrafiltration; or tangential flow filtration (also known as crossflow filtration).

20 Centrifugal filtration involves centrifugation of a liquid through a filter. The filter retains the antigen to be concentrated but does not retain solvent or smaller solutes. As the volume of the filtrate increases, the concentration of the antigen in the retentate also increases. This technique typically uses a fixed angle rotor. Various suitable centrifugal filtration devices are commercially available *e.g.* the products sold under trade marks Centricon™, Vivaspin™ and Spintek™. The cut-off of the filter will be selected such that the antigen of interest remains in the retentate.

25 Ultrafiltration involves the use of hydrostatic pressure to force a liquid against a semipermeable membrane. The filter retains the antigen to be concentrated but does not retain solvent or smaller solutes. Continued application of hydrostatic pressure causes the volume of the filtrate to increase, and thus the concentration of the antigen in the retentate also increases. Many ultrafiltration membranes are commercially available. The molecular weight cut-off (MWCO) of an ultrafiltration
30 membrane determines which solutes can pass through the membrane (*i.e.* into the filtrate) and which are retained (*i.e.* in the retentate). The MWCO of the filter used with the invention will be selected such that substantially all of the antigen of interest remains in the retentate.

35 Tangential flow filtration (TFF) involves passing a liquid tangentially across a filter membrane. The sample side is typically held at a positive pressure relative to the filtrate side. As the liquid flows over the filter, components therein can pass through the membrane into the filtrate. Continued flow causes the volume of the filtrate to increase, and thus the concentration of the antigen in the retentate increases. TFF contrasts with deadend filtration, in which sample is passed through a membrane

rather than tangentially to it. Many TFF systems are commercially available. The MWCO of a TFF membrane determines which solutes can pass through the membrane (*i.e.* into the filtrate) and which are retained (*i.e.* in the retentate). The MWCO of a TFF filter used with the invention will be selected such that substantially all of the antigen of interest remains in the retentate.

5 These three concentration techniques are not mutually exclusive.

Whichever technique is chosen, it preferably increases the concentration of the antigen of interest by at least n -fold relative to the initial concentration, where n is 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80 or more.

Lyophilisation

10 Following antigen concentration, a lyophilisation step may be used.

Lyophilisation typically involves three stages within a chamber: (a) freezing; (b) primary drying; and (c) secondary drying. Step (a) freezes the mobile water of the conjugate. In step (b) the chamber pressure is reduced (*e.g.* to ≤ 0.1 Torr) and heat is applied to the product to cause the frozen water to sublime. In step (c) the temperature is increased to desorb any bound water, such as water of
15 crystallisation, until the residual water content falls to the desired level.

An initial step in a typical lyophilisation, before freezing occurs, is addition of a lyoprotectant. In some embodiments a lyoprotectant may have been added prior to concentration in step (i), but it is preferred to add it instead after concentration has occurred *i.e.* at the end of step (i) or at the start of step (ii). This makes it easier to control the amount of lyoprotectant which is present at the start of
20 lyophilisation freezing.

Thus a one or more lyoprotectants may be added to the concentrated antigen. Suitable lyoprotectants include, but are not limited to, sugar alcohols (such as sorbitol, mannitol, maltitol, erythritol, xylitol) and disaccharides (such as sucrose, trehalose, maltose, lactulose, lactose, cellobiose). Sucrose and mannitol (or a mixture thereof) are preferred lyoprotectants for use with the invention.

25 After lyophilisation, a lyophilised vaccine antigen can be reconstituted. This reconstitution can use water (*e.g.* water for injection, wfi) or buffer (*e.g.* a phosphate buffer, a Tris buffer, a borate buffer, a succinate buffer, a histidine buffer, or a citrate buffer). Buffers will typically be included in the 5-20mM range. A phosphate buffer is preferred.

Step (i) concentrated the first liquid volume of vaccine antigen, providing a composition with the
30 same amount of antigen in a second (reduced) liquid volume. Step (ii) dried this concentrated material. This dried material can be reconstituted in a third liquid volume. If the third volume is greater than the first volume, the overall process has failed to concentrate the antigen. Similarly, if the third volume is greater than the second volume, the reconstitution step has gone backwards in terms of concentration. Thus the third volume is either equal to or, preferably, less than the second
35 volume. Thus the lyophilisation/reconstitution steps can achieve a further antigen concentration.

The TLR agonist may be added to the immunogenic composition following antigen concentration.

Methods of treatment, and administration of immunogenic compositions

The invention provides a method of raising an immune response in a subject, comprising the step of intradermally administering to the subject a TLR agonist and an immunogen.

The invention also provides a composition comprising a TLR agonist and an immunogen, for use in a method of raising an immune response in a subject by intradermal delivery.

The invention also provides the use of a TLR agonist and an immunogen in the manufacture of a intradermal medicament for raising an immune response in a subject. Further details of the medicament are provided above.

The invention is suitable for raising immune responses in human or non-human animal (in particular mammal) subjects. Compositions prepared according to the invention may be used to treat both children and adults.

The immune response stimulated by these methods and uses will generally include an antibody response, preferably a protective antibody response. Methods for assessing antibody responses after immunisation are well known in the art.

15 *Chemical groups*

Unless specifically defined elsewhere, the chemical groups discussed herein have the following meaning when used in present specification:

The term "alkyl" includes saturated hydrocarbon residues including:

- linear groups up to 10 atoms (C_i-C₁₀), or of up to 6 atoms (C_i-C₆), or of up to 4 atoms (C₁-C₄).
20 Examples of such alkyl groups include, but are not limited, to C₁ - methyl, C₂ - ethyl, C₃ - propyl and C₄- n-butyl.
- branched groups of between 3 and 10 atoms (C₃-C₁₀), or of up to 7 atoms (C₃-C₇), or of up to 4 atoms (C₃-C₄). Examples of such alkyl groups include, but are not limited to, C₃ - iso-propyl, C₄ - sec-butyl, C₄ - iso-butyl, C₄ - tert-butyl and C₅ - neo-pentyl.

25 The term "alkylene" refers to the divalent hydrocarbon radical derived from an alkyl group, and shall be construed in accordance with the definition above.

The term "alkenyl" includes monounsaturated hydrocarbon residues including:

- linear groups of between 2 and 6 atoms (C₂-C₆). Examples of such alkenyl groups include, but are not limited to, C₂ - vinyl, C₃ - 1-propenyl, C₃ - allyl, C₄ - 2-butenyl
- 30 - branched groups of between 3 and 8 atoms (C₃-C₈). Examples of such alkenyl groups include, but are not limited to, C₄ - 2-methyl-2-propenyl and C₆ - 2,3-dimethyl-2-butenyl.

The term alkenylene refers to the divalent hydrocarbon radical derived from an alkenyl group, and shall be construed in accordance with the definition above.

The term "alkoxy" includes O-linked hydrocarbon residues including:

- linear groups of between 1 and 6 atoms (Ci-Ce), or of between 1 and 4 atoms (C_{1-C4}). Examples of such alkoxy groups include, but are not limited to, Ci - methoxy, C₂ - ethoxy, C₃ - n-propoxy and C₄ - n-butoxy.

- branched groups of between 3 and 6 atoms (C_{3-C6}) or of between 3 and 4 atoms (C_{3-C4}).

5 Examples of such alkoxy groups include, but are not limited to, C₃ - iso-propoxy, and C₄ - sec-butoxy and tert-butoxy.

Halo is selected from Cl, F, Br and I. Halo is preferably F.

The term "aryl" includes a single or fused aromatic ring system containing 6 or 10 carbon atoms; wherein, unless otherwise stated, each occurrence of aryl may be optionally substituted with up to 5
10 substituents independently selected from (C_{1-C6})alkyl, (Ci-C₆)alkoxy, OH, halo, CN, COOR¹⁴, CF₃ and NR¹⁴R¹⁵; as defined above. Typically, aryl will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl groups include phenyl and naphthyl (each optionally substituted as stated above). Arylene refers the divalent radical derived from an aryl group, and shall be construed in accordance with the definition
15 above.

The term "heteroaryl" includes a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing 1 or 2 N atoms and, optionally, an NR¹⁴ atom, or one NR¹⁴ atom and an S or an O atom, or one S atom, or one O atom; wherein, unless otherwise stated, said heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from (Ci-C₆)alkyl, (Ci-C₆)alkoxy, OH,
20 halo, CN, COOR¹⁴, CF₃ and NR¹⁴R¹⁵; as defined below. Examples of suitable heteroaryl groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl and isoquinolinyl (optionally substituted as stated above). Heteroarylene refers the divalent radical derived from heteroaryl, and shall be construed in
25 accordance with the definition above.

The term "heterocyclyl" is a C-linked or N-linked 3 to 10 membered non-aromatic, mono- or bi-cyclic ring, wherein said heterocycloalkyl ring contains, where possible, 1, 2 or 3 heteroatoms independently selected from N, NR¹⁴, S(O)_q and O; and said heterocycloalkyl ring optionally contains, where possible, 1 or 2 double bonds, and is optionally substituted on carbon with 1 or 2
30 substituents independently selected from (Ci-C₆)alkyl, (Ci-C₆)alkoxy, OH, CN, CF₃, halo, COOR¹⁴, NR¹⁴R¹⁵ and aryl.

In the above definitions R¹⁴ and R¹⁵ are independently selected from H and (Ci-C₆)alkyl.

When a structural formula is defined with a substituent attached to the core of the molecule by an unspecified, or "floating" bond, this definition encompasses the cases where the unspecified
35 substituent is attached to any of the atoms on the ring in which the floating bond is located, whilst complying with the allowable valence for that atom.

In the case of compounds of the invention which may exist in tautomeric forms (*i.e.* in keto or enol forms), reference to a particular compound optionally includes all such tautomeric forms.

General

The term "comprising" encompasses "including" as well as "consisting" *e.g.* a composition
5 "comprising" X may consist exclusively of X or may include something additional *e.g.* X + Y.

The word "substantially" does not exclude "completely" *e.g.* a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.

The term "about" in relation to a numerical value x is optional and means, for example, $x \pm 1$ 0%.

10 Unless specifically stated otherwise, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, *etc.*

Where animal (and particularly bovine) materials are used in the culture of cells, they should be
15 obtained from sources that are free from transmissible spongiform encephalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.

Where a compound is administered to the body as part of a composition then that compound may alternatively be replaced by a suitable prodrug.

20 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1. HI titers provided by intradermal and intramuscular delivery of influenza antigen and TLR agonists following two immunizations.

MODES FOR CARRYING OUT THE INVENTION

Immunogen concentration

25 *Centrifugal filtration*

Centrifugal filtration used a Millipore™ device with a 10kDa cut-off, operated at 5000rpm.

Three centriugation durations were tested: 15, 30 and 45 minutes. The retentate (concentrate) and filtrate were checked to see the location of an influenza virus hemagglutinin. Figure 1 shows that the antigen is still in the retentate after 45 minutes. Antigen concentration was 3-fold after 15 minutes,
30 6-fold after 30 minutes, and 13-fold after 45 minutes. Antigen recovery was 40% after 15 minutes, 41% after 30 minutes, and 55% after 45 minutes. Thus 45 minutes was chosen for further work.

In further work, antigen was lyophilised after centrifugation, to provide further concentration. Sucrose was used as the lyoprotectant, alone (at two different concentrations) or with mannitol. Lyophilised material was reconstituted. The reconstituted samples contained visible aggregates.
35 Relative to the starting material, HA content (measured by ELISA) was concentrated as follows:

Treatment	Concentration (x)
Starting material	1.0 x
Addition of sucrose	2.3 x
Addition of sucrose (higher concentration)	1.3 x
Addition of sucrose + mannitol	0.8 x
Sucrose, lyophilise, reconstitute	13.3 x
Sucrose+mannitol, lyophilise, reconstitute	8.5 x
Centrifuge, sucrose, lyophilise, reconstitute	25.2 x
Centrifuge, sucrose (higher), lyophilise, reconstitute	28.4 x

Thus the combination of centrifugation and lyophilisation can provide a >25-fold concentration in influenza virus HA content. The two centrifuged samples were also assessed by SRID and they showed a 21.1x and 35.1x increase in HA content, with the higher sucrose level again giving better results.

Ultrafiltration

Ultrafiltration used an Amicon™ stir cell concentrator with a 10kDa cut-off membrane made from regenerated cellulose, operated under pressurised nitrogen for 1 hour.

If a lyophilisation was added, followed by reconstitution back into the pre-lyophilisation volume, the reconstituted material had a HA concentration (as measured by SRID) comparable to the starting material, indicating no loss of functional antigen. The reconstituted material was stable for >2 weeks.

Intradermal delivery of immunogenic compositions

Influenza

Immunization of Balb/c mice with 100µl or 20µl immunogenic composition was carried out using both intramuscular delivery and intradermal delivery. The composition included a trivalent influenza vaccine with a 1µg HA dose of each of X181 H1N1 Cal, X187 H3N2 Perth and B/Brisbane and one of a group of adjuvants including TLR agonists. Mice were anaesthetized before immunization. For the mice receiving intradermal immunization, an area on the back of the mouse was shaved or plucked to remove the hair at the injection site. The site was swabbed with 70% ethanol. The needle was inserted, bevel up, with the needle held nearly parallel to the plane of the skin. Both the mice receiving intramuscular and intradermal immunization, a number of different TLR agonists were used and the doses administered, the total volume of the composition used and the route of administration are shown in Table 1 below. Using volumes of 50µl or less per site for intradermal delivery avoids tissue trauma.

25 Table 1

Group	Adjuvant	Dose	Total volume	Route
1	-	-	100 µl	IM
2	MF59	(1:1)	100 µl	IM

3	-	-	100 μl	IM
4	-	-	20 μl	ID
5	Tla	50 μg	20 μl	ID
6	Tib	50 μg	20 μl	ID
7	Tib	100 μg	20 μl	ID
8	T2	50 μg	20 μl	ID
9	LTK63	5 μg	20 μl	ID
10	a-GalCer	5 μg	20 μl	ID
11	MPLA	25 μg	20 μl	ID
12	MF59	(1:1)	20 μl	ID

The Tla adjuvant was formulated by dispersion in 0.05% carboxymethyl cellulose or 0.05% Tween80 and sonicated in a water bath. The Tib adjuvant was formulated by dispersion in IX and sonicated in a water bath. The T2 adjuvant was formulated by dispersion in 10mM ammonia solution and sonicated in a water bath. The LTK63 adjuvant [114] was formulated in 0.05M sodium phosphate and 0.2M L-arginine. The a-GalCer adjuvant was formulated in water and 0.05% Tween20 and sonicated in a water bath for 30 minutes at 37°C. The MPL adjuvant was formulated by aqueous dispersion using 0.5% TEoA/WFI.

Two immunizations were carried out 28 days apart, and individual samples were analyzed for anti-H1N1, anti H3N2 and anti-B hemagglutination inhibition (HI) titers 14 and 28 days after the first immunization and 14 days after the second immunization. Figures 1-3 show the HI titers for anti-H1N1, anti-H3N2 and anti-B respectively.

When administered intradermally, the influenza antigens induce comparable HI titers to those induced following intramuscular administration. An improved immune response was provided following a second intradermal immunization in the presence each of the TLR agonists compared to intradermal immune in the absence of a TLR agonist. The immune response provided by intradermal immunization with antigen alone or antigen plus MF59 is comparable to the immune response provided by intramuscular immunization with antigen alone or antigen plus MF59.

Intradermal immunization with Tib (100 μg) or LTK63 (5 μg) provided a significantly improved immune response compared to both intradermal or intramuscular immunization using antigen alone.

Neisseria meningitidis

Immunization of CD1 mice with 100 μl immunogenic composition comprising a 10 μg dose of three *N. meningitidis* B antigens [74] and one of a group of adjuvants including TLR agonists was carried out using both intramuscular delivery and intradermal delivery. Mice were anaesthetized before immunization. An area on the back of the mouse was shaved or plucked to remove the hair at the injection site. The site was swabbed with 70% ethanol. The needle was inserted, bevel up, with the

needle held nearly parallel to the plane of the skin. A number of different TLR agonists were used and the doses administered, the total volume of the composition used and the route of administration are shown in Table 2 below.

Group	Adjuvant	Dose	Total volume	Route
1	-	-	100 ul	IM
2	-	-	100 µl	ID
3	T1a	100 µg	100 µl	IM
4	T1a	100 µg	100 µl	ID
5	T1b	100 µg	100 µl	IM
6	T1b	100 µg	100 µl	ID
7	T2	100 µg	100 µl	IM
8	T2	100 µg	100 µl	ID
9	Alum/T1c	100 µg	100 µl	IM
10	Alum/T1c	100 µg	100 µl	ID

- 5 The T1a adjuvant was formulated by dispersion in 0.05% carboxymethyl cellulose or 0.05% Tween80 and sonicated in a water bath. The Tib adjuvant was formulated by dispersion in IX and sonicated in a water bath. The T2 adjuvant was formulated by dispersion in 10mM NH₃ solution and sonicated in a water bath.

Immunizations were carried out, and individual samples were analysed for bactericidal activity.

- 10 Figure 4 shows the bactericidal titers for each of the compositions tested.

When administered intradermally, the MenB antigens induce higher bactericidal titers to those induced following intramuscular administration even without the presence of TLR agonists. Intradermal immunization with T2 provides an improved immune response compared to combination of the antigens with other adjuvants. The immune response provided following intradermal administration of meningitidis antigens and TLR agonists is comparable to the immune response provided following intramuscular administration of meningitidis antigens and TLR agonists.

It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

REFERENCES

- [1] Prausnitz *et al.* (2009) *Curr Top Microbiol Immunol.* 333 :369-93.
- [2] Kang *et al.* (2012) *Expert Rev Vaccines.* 11(5):547-60.
- [3] Davidson *et al.* (2008) *Chemical Engineering Research and Design* 86: 1196-1206.
- [4] Carey *et al.* (2011) *PLoS ONE* 6(7): e22442.
- [5] Bal *et al.* (2010) *J Control Release.* 147:21 8-24.
- [6] Donnelly *et al.* (2011) *Pharm Res* 28:41-57.
- [7] Koutsonanos *et al.* (2009) *PLoS ONE* 4(e): e4773.
- [8] Quan *et al.* (2009) *PLoS ONE* 4(9):e7152.
- [9] Matsuo *et al.* (2012) *J Control Release* 161:10-17.
- [10] US-2011/12509.
- [11] WO2009/040548.
- [12] Lee *et al.* (2008) *Biomaterials* 29(13):21 13-24.
- [13] WO2007/030477.
- [14] US-6945952.
- [15] US-721 1062.
- [16] Sullivan *et al.* (2010) *Nature Med* 16:915-920.
- [17] US-2009/0182306
- [18] US-71 82747.
- [19] Oh *et al.* (2006) American Association of Pharmaceutical Scientists, 2006 Annual Meeting and Exposition. *The AAPS Journal.* 8(S2).
- [20] WO2007/127976.
- [21] Matsuo *et al.* (2012) *J Control Release.* 160(3):495-501 .
- [22] Koutsonanos *et al.* (2012) *Sci Rep.* 2:357.
- [23] EP-A-2289843.
- [24] Gill & Prausnitz (2007) *J Control Release* 117:227-37.
- [25] WO2007/124393.
- [26] WO2007/061 964.
- [27] WO2007/059289.
- [28] Jin *et al.* (2009) *Biomed Microdevices.* 11(6): 1195-203.
- [29] Vrdoljak *et al.* (2012) *J Control Release* 159:34-42.
- [30] Rosenberg *et al.* (2010) *J Immunol* 184: 136.20.
- [31] US-4,666,886.
- [32] WO2009/118296.


- [33] WO2008/005555.
- [34] WO2009/1 11337.
- [35] WO2009/06708 1.
- [36] WO2007/040840.
- [37] WO201 0/01491 3.
- [38] WO201 1/049677.
- [39] WO2012/03 1140
- [40] WO201 1/1 19759.
- [41] US2010/0143301 .
- [42] GB-A-222021 1.
- [43] Myers *et al.* (1990) pages 145-156 of *Cellular and molecular aspects of endotoxin reactions*.
- [44] Ulrich (2000) Chapter 16 (pages 273-282)
- [45] Johnson *et al.* (1999) *J Med Chem* 42:4640-9.
- [46] Baldrick *et al.* (2002) *Regulatory Toxicol Pharmacol* 35:398-413.
- [47] Coler *et al.* (2011) *PLoS ONE* 6(1):e16333.
- [48] Johnson *et al.* (1999) *Bioorg Med Chem Lett* 9:2273-2278.
- [49] Evans *et al.* (2003) *Expert Rev Vaccines* 2:219-229.
- [50] Bazin *et al.* (2006) *Tetrahedron Lett* 47:2087-92.
- [51] Wong *et al.* (2003) *J Clin Pharmacol* 43(7):735-42.
- [52] US2005/02155 17.
- [53] WO03/01 1223.
- [54] WO2007/053455.
- [55] De Libero *et al.*, *Nature Reviews Immunology*, 2005, 5: 485-496.
- [56] US patent 5,936,076.
- [57] Oki *et al.*, *J. Clin. Investig.*, 113: 1631-1640.
- [58] US2005/0 192248.
- [59] Yang *et al.*, *Angew. Chem. Int. Ed.*, 2004, 43: 3818-3822.
- [60] WO2008/047174.
- [61] WO2008/047249.
- [62] WO2005/1 02049.
- [63] Goff *et al.*, *J. Am. Chem. Soc.*, 2004, 126: 13602-13603.
- [64] WO03/105769.
- [65] Peppoloni *et al.* (2003) *Expert Rev Vaccines* 2:285-93.
- [66] W095/1721 1.
- [67] da Hora *et al.* (2011) *Vaccine* 29: 1538-44.

- [68] WO93/13202.
- [69] Pizza *et al.* (2000) *Int J Med Microbiol* 290:455-61 .
- [70] W098/1 8928.
- [71] Feng *et al.* (2005) *Acta Biochim Biophys Sin (Shanghai)*. 37(2): 126-32.
- [72] Treanor *et al.* (1996) *J Infect Dis* 173 :1467-70.
- [73] Keitel *et al.* (1996) *Clin Diagn Lab Immunol* 3:507-10.
- [74] Giuliani *et al.* (2006) *Proc Natl Acad Sci USA*. 103 :10834-9.
- [75] WO03/097091 .
- [76] Cassone & Torosantucci (2006) *Expert Rev Vaccines* 5:859-67.
- [77] *Research Disclosure*, 453077 (Jan 2002).
- [78] EP-A-0372501 .
- [79] EP-A-0378881 .
- [80] EP-A-0427347.
- [81] W093/17712.
- [82] WO94/03208.
- [83] W098/58668.
- [84] EP-A-0471 177.
- [85] WO91/01 146.
- [86] Falugi *et al.* (2001) *Eur J Immunol* 31:38 16-3824.
- [87] Baraldo *et al.* (2004) *Infect Immun* 72(8):4884-7.
- [88] EP-A-0594610.
- [89] Ruan *et al.* (1990) *J Immunol* 145 :3379-3384.
- [90] WO00/56360.
- [91] Kuo *et al.* (1995) *Infect Immun* 63:2706-13.
- [92] Michon *et al.* (1998) *Vaccine*. 16:1732-41 .
- [93] WO02/091998.
- [94] WO01/72337.
- [95] WO00/61 761 .
- [96] WO00/33882
- [97] US patent 4,761 ,283.
- [98] US patent 4,356,170.
- [99] US patent 4,882,3 17.
- [100] US patent 4,695,624.
- [101] *Mol. Immunol.*, 1985, **22**, 907-919
- [102] EP-A-0208375.

- [103] Bethell G.S. *et al*, *J. Biol. Chem.*, 1979, **254**, 2572-4
- [104] Hearn M.T.W. *J. Chromatogr.*, 1981, **218**, 509-18
- [105] WO00/10599.
- [106] Gever *et al.*, *Med. Microbiol. Immunol*, 165 : 171-288 (1979).
- [107] US patent 4,057,685.
- [108] US patents 4,673,574; 4,761,283; 4,808,700.
- [109] US patent 4,459,286.
- [110] US patent 4,965,338.
- [III] US patent 4,663,160.
- [112] WO2007/000343.
- [113] *Remington: The Science and Practice of Pharmacy* (Gennaro, 2000; 20th edition, ISBN: 0683306472)
- [114] Tritto *et al.* (2007) *J. Immunol.* 179:5346-5357.

CLAIMS

1. An intradermal delivery system comprising a solid biodegradable microneedle, wherein the microneedle comprises a TLR agonist and an immunogen.
2. An intradermal delivery system comprising a solid microneedle, wherein the microneedle comprises a TLR agonist and a bacterial antigen.
3. An intradermal delivery system comprising an immunogenic composition comprising a TLR agonist, wherein the TLR agonist is:
 - (a) a benzonaphthyridine TLR7 agonist;
 - (b) a TLR7 agonist having formula T1:



wherein

R^1 is H, Ci-C₆alkyl, -C(R⁵)₂OH, -VR⁵, -VR⁶, -L²R⁵, -L²R⁶, -OL²R⁵, or -OL²R⁶;

L¹ is -C(O)- or -O-;

L² is Ci-C₆alkylene, C₂-C₆alkenylene, arylene, heteroarylene or $((CR^4R^4)_pO)_q(CH_2)_p$, wherein the Ci-C₆alkylene and C₂-C₆alkenylene of L² are optionally substituted with 1 to 4 fluoro groups;

each L³ is independently selected from Ci-C₆alkylene and $((CR^4R^4)_pO)_q(CH_2)_p$,

wherein the Ci-C₆alkylene of L³ is optionally substituted with 1 to 4 fluoro groups;

L⁴ is arylene or heteroarylene;

R² is H or Ci-C₆alkyl;

R³ is selected from Ci-C₄alkyl, -L³R⁵, -L³R⁷, -L³L⁴L³R⁷, -L³L⁴R⁵, -L³L⁴L³R⁵, -OL³R⁵, -OL³R⁷, -OL³L⁴R⁷, -OL³L⁴L³R⁷, -OR⁸, -OL³L⁴R⁵, -OL³L⁴L³R⁵ and -C(R⁵)₂OH;

each R⁴ is independently selected from H and fluoro;

R⁵ is -P(0)(OR⁹)₂,

R⁶ is -CF₂P(0)(OR⁹)₂ or -C(0)OR¹⁰;

R⁷ is -CF₂P(0)(OR⁹)₂ or -C(0)OR¹⁰;


R⁸ is H or Ci-C₄alkyl;

each R⁹ is independently selected from H and Ci-C₆alkyl;

R¹⁰ is H or Ci-C₄alkyl;

each p is independently selected from 1, 2, 3, 4, 5 and 6, and
q is 1, 2, 3 or 4;

(c) a TLR2 agonist having formula T2:



(T 2)

wherein:

R^1 is H, $-C(O)-C_{7-8}alkyl$ or $-C(O)-C_{6}alkyl$;

R^2 is $C_{7-8}alkyl$;

R^3 is $C_{7-8}alkyl$;

L_1 is $-CH_2OC(O)-$, $-CH_2O-$, $-CH_2NR^7C(O)-$ or $-CH_2OC(O)NR^7-$;

L_2 is $-OC(O)-$, $-O-$, $-NR^7C(O)-$ or $-OC(O)NR^7-$;

R^4 is $-L_3R^5$ or $-L_4R^5$;

R^5 is $-N(R^7)_2$, $-OR^7$, $-P(O)(OR^7)_2$, $-C(O)OR^7$, $-NR^7C(O)L_3R^8$, $-NR^7C(O)L_4R^8$, $-OL_3R^6$, $-C(O)NR^7L_3R^8$, $-C(O)NR^7L_4R^8$, $-S(O)_2OR^7$, $-OS(O)_2OR^7$, $C_{6}aryl$, a $C_{6}aryl$, a $C_{10}aryl$, a $C_{14}aryl$, 5 to 14 ring membered heteroaryl containing 1 to 3 heteroatoms selected from O, S and N, $C_3-C_{3}cycloalkyl$ or a 5 to 6 ring membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O, S and N, wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R^5 are each unsubstituted or the aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R^5 are each substituted with 1 to 3 substituents independently selected from $-OR^9$, $-OL_3R^6$, $-OL_4R^6$, $-OR^7$, and $-C(O)OR^7$;

L_3 is a $C_{1-4}alkylene$, wherein the $C_{1-4}alkylene$ of L_3 is unsubstituted, or the $C_{1-4}alkylene$ of L_3 is substituted with 1 to 4 R^6 groups, or the $C_{1-4}alkylene$ of L_3 is substituted with 2 $C_{1-2}alkyl$ groups on the same carbon atom which together, along with the carbon atom they are attached to, form a $C_3-C_3cycloalkyl$;

L_4 is $-((CR^7R^7)_pO)_q(CR^{10}R^{10})_p-$ or $-(CR^{11}R^{11})((CR^7R^7)_pO)_q(CR^{10}R^{10})_p-$, wherein each R^{11} is a $C_{1-2}alkyl$ groups which together, along with the carbon atom they are attached to, form a $C_3-C_3cycloalkyl$;

each R^6 is independently selected from halo, $C_{1-2}alkyl$, $C_{1-2}alkyl$ substituted with 1-2 hydroxyl groups, $-OR^7$, $-N(R^7)_2$, $-C(O)OH$, $-C(O)N(R^7)_2$, $-P(O)(OR^7)_2$, a $C_{6}aryl$, a $C_{10}aryl$ and a $C_{14}aryl$;

each R^7 is independently selected from H and $C_{1-2}alkyl$;

R^8 is selected from $-SR^7$, $-C(O)OH$, $-P(O)(OR^7)_2$, and a 5 to 6 ring membered heterocycloalkyl containing 1 to 3 heteroatoms selected from O and N;

R^9 is phenyl;

each R¹⁰ is independently selected from H and halo;
each p is independently selected from 1, 2, 3, 4, 5 and 6, and
q is 1, 2, 3 or 4.

4. An intradermal delivery system comprising an immunogenic composition comprising a TLR agonist and an immunogen, wherein the TLR agonist is selected from a TLR5 agonist, a TLR1 agonist and a TLR6 agonist.
5. An intradermal delivery system comprising an immunogenic composition comprising a CDId agonist or a CLR agonist and an immunogen,
6. The intradermal delivery system of claim 10, wherein the CDId agonist is an α -glycosylceramide.
7. An intradermal delivery system comprising an immunogenic composition comprising a mutant *E. coli* heat labile toxin and an immunogen,
8. The intradermal delivery system of any one of claims 1 or 2, wherein the TLR agonist is a TLR7 agonist.
9. The intradermal delivery system of any one of claims 1 or 2, wherein the TLR agonist is:
 - a) a TLR4 agonist;
 - b) a TLR5 agonist;
 - c) a TLR1 agonist;
 - d) a TLR6 agonist; or
 - e) a TLR9 agonist.
10. The intradermal delivery system of claim 9, wherein the TLR4 agonist is MPL.
11. The intradermal delivery system of any one of claims 2-10 comprising a solid biodegradable microneedle.
12. A process for preparing an intradermal delivery system comprising a solid microneedle, wherein the microneedle comprises a TLR agonist and an immunogen, wherein the method comprises the steps of a) mixing an immunogen and a TLR agonist to form an immunogenic composition in which the immunogen has a concentration of 10mg/ml-50mg/ml and the TLR agonist has a concentration of 0.1mg/ml-10mg/ml and b) drying the immunogenic composition to form a solid microneedle.

FIG. 1




FIG. 2





FIG. 3



INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2014/051860

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos. :

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos. :

I (completely) ; 8-II (partially)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/051860

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K39/39
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PATTANI ADITYA ET AL: "Mi croneedl e mediated intradermal del ivery of adjuvanted recombi nant HIV-1 CN54gpl40 effecti vely primes mucosal boost i nocul ati ons" , JOURNAL OF CONTROLLED RELEASE, vol . 162, no. 3, September 2012 (2012-09) , pages 529-537 , XP002715004, page 529, r ight-hand col umn, paragraph 1 - page 530, l eft-hand col umn, paragraph 1 page 530, r ight-hand col umn, paragraph 2 page 534, l eft-hand col umn, paragraph 2 - page 535, r ight-hand col umn, paragraph 1 page 536, l eft-hand col umn, l ast paragraph ----- -/- .</p>	1,9-11

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 March 2014

Date of mailing of the international search report

07/07/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040,
 Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez , B

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2014/051860

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DEMUTH P ET AL: "Engi neered mi croneedl e arrays for transcutaneous HIV vacci ne del i very" , RETROVI RO LOGY, BIOMED CENTRAL LTD. , LONDON , GB, vol . 9 , no. Suppl 2 , 13 September 2012 (2012-09-13) , page P334, XP021116574, ISSN : 1742-4690, DOI : 10. 1186/1742-4690-9-S2-P334 the whol e document	1, 11
Y	Wo 02/085446 A2 (ALZA CORP [US]) 31 October 2002 (2002-10-31) page 3, paragraph 0009 - page 5, paragraph 00013 page 9, paragraph 00033 - page 12, paragraph 00039 ; cl aims ; exampl es	1,8-11
Y	w0 2011/151723 A2 (NOVARTIS AG [CH] ; KOMMAREDDY SUSHMA [US] ; SCAMPINI AMANDA [US] ; BAUDNE) 8 December 2011 (2011-12-08) page 7, line 1 - page 8, line 29 page 11, line 24 - line 28 page 20, line 25 - line 32	1,8-11
X,P	GU0 LEI ET AL: "Enhanced transcutaneous immuni zati on via di ssol ving mi croneedl e array loaded with liposome encapsul ated anti gen and adjuvant" , INTERNATIONAL JOURNAL OF PHARMACEUTICS (KIDLINGTON) , vol . 447 , no. 1-2 , Apri l 2013 (2013-04) , pages 22-30, XP002715005 , page 22, right-hand col umn, paragraph 2 - page 23, left-hand col umn, paragraph 1 page 23, left-hand col umn, paragraph 4 page 24, left-hand col umn, paragraph 3 - right-hand col umn, paragraph 3 page 28, right-hand col umn, paragraph 2 - page 29, left-hand col umn, paragraph 2	1,9
A	ELSA E KIS ET AL: "Devi ces for i ntradermal vacci nati on" , VACCINE, ELSEVI ER LTD, GB, vol . 30, no. 3, 6 November 2011 (2011-11-06) , pages 523-538, XP028348164, ISSN : 0264-410X, DOI : 10. 1016/J .VACCINE.2011 . 11.020 [retri eved on 2011-11-11] the whol e document	1,8-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2014/051860

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
wo 02085446	A2	31-10-2002	BR 0209041 A 18-01-2005
			CA 2444551 AI 31-10-2002
			CN 1602216 A 30-03-2005
			EP 1383571 A2 28-01-2004
			JP 4382356 B2 09-12-2009
			JP 2004538048 A 24-12-2004
			KR 20040014502 A 14-02-2004
			MX PA03009601 A 06-12-2004
			NO 20034683 A 09-12-2003
			US 2002193729 AI 19-12-2002
			US 2006074377 AI 06-04-2006
			US 2009143724 AI 04-06-2009
			wo 02085446 A2 31-10-2002
wo 2011151723	A2	08-12-2011	AU 2011262309 AI 20-12-2012
			CA 2801149 AI 08-12-2011
			CN 103096921 A 08-05-2013
			EA 201291437 AI 30-05-2013
			EP 2575872 A2 10-04-2013
			JP 2013534912 A 09-09-2013
			KR 20130109004 A 07-10-2013
			US 2013224245 AI 29-08-2013
			wo 2011151723 A2 08-12-2011

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (completely) ; 8-11 (partially)

Intradermal delivery system comprising a solid biodegradable microneedle comprising a TLR agonist and an immunogen

2. claims: 2 (completely) ; 8-11 (partially)

Intradermal delivery system comprising a solid microneedle comprising a TLR agonist and a bacterial antigen

3. claims: 3, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a TLR7 agonist

4. claims: 3, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a TLR2 agonist of formula T2

5. claims: 4, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a TLR5 agonist and an immunogen

6. claims: 4, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a TLR1 agonist and an immunogen

7. claims: 4, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a TLR6 agonist and an immunogen

8. claims: 6 (completely) ; 5, 11 (partially)

Intradermal delivery system comprising an immunogenic composition comprising a CD1d agonist and an immunogen

9. claims: 5, 11 (all partially)

Intradermal delivery system comprising an immunogenic composition comprising a CLR agonist and an immunogen

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. claims: 7 (completely) ; 11 (partially)

Intradermal delivery system comprising an immunogenic composition comprising a mutant E. coli heat labile toxin and an immunogen

11. claim: 12

Process for preparing an intradermal delivery system comprising a solid microneedle comprising a TLR agonist and an immunogen by mixing the immunogen and the TLR antigen and drying to form a solid microneedle
